<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Imatinib</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Imatinib">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Imatinib</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Imatinib</b>, sold under the brand name <b>Gleevec</b> among others, is an oral chemotherapy medication used to treat cancer.<span class="mw-ref" id="cite_ref-AHFS2017_2-1"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph<sup>+</sup>), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome.<span class="mw-ref" id="cite_ref-AHFS2017_2-2"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is taken by mouth.<span class="mw-ref" id="cite_ref-AHFS2017_2-3"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Imatinib</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Imatinib2DACS.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Imatinib2DACS.svg.png" data-file-width="694" data-file-height="383" data-file-type="drawing" height="138" width="250"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Imatinib_xtal-2007-balls-and-sticks.png" tppabs="https://ptable.com/wiki/compounds/I/m/Imatinib_xtal-2007-balls-and-sticks.png" data-file-width="3987" data-file-height="1158" data-file-type="bitmap" height="81" width="280"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Gleevec, Glivec, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>STI-571, imatinib mesylate (USAN <small><abbr>US</abbr></small>)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/imatinib-mesylate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/imatinib-mesylate.html'" tppabs="https://www.drugs.com/monograph/imatinib-mesylate.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a606018.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a606018.html'" tppabs="https://medlineplus.gov/druginfo/meds/a606018.html" class="external text external">a606018</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Imatinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Imatinib'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Imatinib" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Imatinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Imatinib'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Imatinib" class="external text external">Imatinib</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Imatinib&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Imatinib&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Imatinib&SearchType=BasicSearch" class="external text external">Imatinib</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-0"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-1"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Tyrosine kinase inhibitor<span class="mw-ref" id="cite_ref-AHFS2017_2-0"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XE01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XE01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XE01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XE01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">CA</abbr></small>:<span> </span> ℞-only<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>98%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>95%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>liver (mainly CYP3A4-mediated)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>18 h (imatinib)<br>40 h (active metabolite)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Fecal (68%) and kidney (13%)</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">4-[(4-methylpiperazin-1-yl)methyl]-<i>N</i>-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152459-95-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152459-95-5'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152459-95-5" class="external text external">152459-95-5</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup> <br><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=220127-57-1&title=  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=220127-57-1&title='" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=220127-57-1&title=" class="external text external">220127-57-1</a> (mesilate)</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/5291  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/5291'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/5291" class="external text external">5291</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687" class="external text external">5687</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00619  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00619'" tppabs="https://www.drugbank.ca/drugs/DB00619" class="external text external">DB00619</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.5101.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.5101.html'" tppabs="http://www.chemspider.com/Chemical-Structure.5101.html" class="external text external">5101</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=BKJ8M8G5HI  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=BKJ8M8G5HI'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=BKJ8M8G5HI" class="external text external">BKJ8M8G5HI</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D08066  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D08066'" tppabs="https://www.kegg.jp/entry/D08066" class="external text external">D08066</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45783  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45783'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45783" class="external text external">CHEBI:45783</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL941  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL941'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL941" class="external text external">ChEMBL941</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PDB ligand</th><td><div class="plainlist"><ul><li>STI (<span><a href="javascript:if(confirm('https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=STI  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=STI'" tppabs="https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=STI" class="external text external">PDBe</a></span>, <span><a href="javascript:if(confirm('http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=STI&polymericType=Any  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=STI&polymericType=Any'" tppabs="http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=STI&polymericType=Any" class="external text external">RCSB<span>&nbsp;</span>PDB</a></span>)</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID3037125  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID3037125'" tppabs="https://comptox.epa.gov/dashboard/DTXSID3037125" class="external text external">DTXSID3037125</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.122.739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.122.739'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.122.739" class="external text external">100.122.739</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>29</sub><span>H</span><sub>31</sub><span>N</span><sub>7</sub><span>O</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td>493.603 g/mol<br>589.7 g/mol (mesilate)<span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=Cc1ccc%28cc1Nc2nccc%28n2%29c3cccnc3%29NC%28%3DO%29c4ccc%28cc4%29CN5CCN%28CC5%29C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=Cc1ccc%28cc1Nc2nccc%28n2%29c3cccnc3%29NC%28%3DO%29c4ccc%28cc4%29CN5CCN%28CC5%29C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=Cc1ccc%28cc1Nc2nccc%28n2%29c3cccnc3%29NC%28%3DO%29c4ccc%28cc4%29CN5CCN%28CC5%29C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:KTUFNOKKBVMGRW-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459451238&page2=Imatinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459451238&page2=Imatinib'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459451238&page2=Imatinib" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


<p>Common side effects include vomiting, diarrhea, muscle pain, headache, and rash.<span class="mw-ref" id="cite_ref-AHFS2017_2-4"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Severe side effects may include fluid retention, gastrointestinal bleeding, bone marrow suppression, liver problems, and heart failure.<span class="mw-ref" id="cite_ref-AHFS2017_2-5"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Use during pregnancy may result in harm to the baby.<span class="mw-ref" id="cite_ref-AHFS2017_2-6"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Imatinib works by stopping the Bcr-Abl tyrosine-kinase.<span class="mw-ref" id="cite_ref-AHFS2017_2-7"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> This can slow growth or result in programmed cell death of certain types of cancer cells.<span class="mw-ref" id="cite_ref-AHFS2017_2-8"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p>Imatinib was approved for medical use in the United States in 2001.<span class="mw-ref" id="cite_ref-AHFS2017_2-9"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.<span class="mw-ref" id="cite_ref-WHO21st_3-0"><a href="#cite_note-WHO21st-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> The wholesale cost in the developing world is about US$1,386.49–19,162.50 a year.<span class="mw-ref" id="cite_ref-ERC2014_4-0"><a href="#cite_note-ERC2014-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> In the United States a typical dose for a year has a wholesale cost of $84,408.78,<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> while in the United Kingdom the NHS was paying about £20,980 ($<span>27,973</span>) in 2016.<span class="mw-ref" id="cite_ref-BNF69_6-0"><a href="#cite_note-BNF69-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> A generic version became available in the UK as of 2017.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. In 2006 the FDA expended approved use to include Dermatofibrosarcoma protuberans (DFSP), Myelodysplastic/myeloproliferative diseases (MDS/MPD), Aggressive systemic mastocytosis.</p>

<p>(ASM).<span class="mw-ref" id="cite_ref-cancernetwork.com_8-0"><a href="#cite_note-cancernetwork.com-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Chronic_myelogenous_leukemia">Chronic myelogenous leukemia</h3></summary>
    
<p>The U.S. Food and Drug Administration (FDA) has approved imatinib as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. The drug is approved in multiple contexts of Philadelphia chromosome-positive CML, including after stem cell transplant, in blast crisis, and newly diagnosed.<span class="mw-ref" id="cite_ref-FDA_9-0"><a href="#cite_note-FDA-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

<p>Due in part to the development of imatinib and related drugs, the five year survival rate for people with chronic myeloid leukemia increased from 31% in 1993, to 59% in 2009,<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> to 70% in 2016.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Gastrointestinal_stromal_tumors">Gastrointestinal stromal tumors</h3></summary>
    
<p>The FDA first granted approval for advanced GIST patients in 2002. On 1 February 2012, imatinib was approved for use after the surgical removal of KIT-positive tumors to help prevent recurrence.<span class="mw-ref" id="cite_ref-onclive_12-0"><a href="#cite_note-onclive-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> The drug is also approved in unresectable KIT-positive GISTs.<span class="mw-ref" id="cite_ref-FDA_9-1"><a href="#cite_note-FDA-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Dermatofibrosarcoma_protuberans_(DFSP)"><i>Dermatofibrosarcoma protuberans (DFSP)</i></h3></summary>
    
<p>The FDA granted approval for the treatment of DFSP patients in 2006.<span class="mw-ref" id="cite_ref-cancernetwork.com_8-1"><a href="#cite_note-cancernetwork.com-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> Specifically adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). Prior to approval DFSP was considered unresponsive to chemotherapy treatments.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Other">Other</h3></summary>
    
<p>The FDA has approved imatinib for use in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/ myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangements, aggressive systemic mastocytosis without or an unknown D816V c-KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (CHIC2 allele deletion) or FIP1L1-PDGFRα fusion kinase negative or unknown, unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.<span class="mw-ref" id="cite_ref-FDA_9-2"><a href="#cite_note-FDA-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> On 25 January 2013, Gleevec was approved for use in children with Ph+ ALL.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p>For treatment of progressive plexiform neurofibromas associated with neurofibromatosis type I, early research has shown potential for using the c-KIT tyrosine kinase blocking properties of imatinib.<span class="mw-ref" id="cite_ref-pmid18984156_14-0"><a href="#cite_note-pmid18984156-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications_and_cautions">Contraindications and cautions</h2></summary>
    
<p>The only known contraindication to imatinib is hypersensitivity to imatinib.<span class="mw-ref" id="cite_ref-EMC_18-0"><a href="#cite_note-EMC-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> Cautions include:<span class="mw-ref" id="cite_ref-MSR_19-0"><a href="#cite_note-MSR-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>
<ul><li>Hepatic impairment</li>
<li>Risk of severe CHF or left ventricular dysfunction, especially in patients with comorbidities</li>
<li>Pregnancy, risk of embryo-fetal toxicity</li>
<li>Risk of fluid retention</li>
<li>Risk of growth stunting in children or adolescents</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Bcr_abl_STI_1IEP.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bcr_abl_STI_1IEP.png" data-file-width="1361" data-file-height="1000" data-file-type="bitmap" height="162" width="220"><div class="thumbcaption" style="text-align: left">bcr-abl kinase (green), which causes CML, inhibited by imatinib (red; small molecule).</div></div></div>

<p>The most common side effects include nausea, vomiting, diarrhea, headaches, leg aches/cramps, fluid retention, visual disturbances, itchy rash, lowered resistance to infection, bruising or bleeding, loss of appetite;<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> weight gain, reduced number of blood cells (neutropenia, thrombocytopenia, anemia), and edema.<span class="mw-ref" id="cite_ref-AustriaCodex_21-0"><a href="#cite_note-AustriaCodex-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span>
Although rare, restoration of hair color has been reported as well.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span>
Severe congestive cardiac failure is an uncommon but recognized side effect of imatinib and mice treated with large doses of imatinib show toxic damage to their myocardium.<span class="mw-ref" id="cite_ref-pmid16862153_24-0"><a href="#cite_note-pmid16862153-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>

<p>If imatinib is used in prepubescent children, it can delay normal growth, although a proportion will experience catch-up growth during puberty.<span class="mw-ref" id="cite_ref-pmid21592517_25-0"><a href="#cite_note-pmid21592517-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Overdose">Overdose</h2></summary>
    
<p>Medical experience with imatinib overdose is limited.<span class="mw-ref" id="cite_ref-TGA_26-0"><a href="#cite_note-TGA-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> Treatment is supportive.<span class="mw-ref" id="cite_ref-TGA_26-1"><a href="#cite_note-TGA-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> Imatinib is highly plasma protein-bound:<span class="mw-ref" id="cite_ref-TGA_26-2"><a href="#cite_note-TGA-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> dialysis is unlikely to be helpful removing imatinib.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:434px"><img src="../I/m/Mechanism_imatinib.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Mechanism_imatinib.svg.png" data-file-width="432" data-file-height="268" data-file-type="drawing" height="268" width="432"><div class="thumbcaption" style="text-align: left">Mechanism of action of imatinib</div></div></div>
<table class="infobox" style="width:22em;float:left; clear:left; margin: 0.5em 1em 0.5em 0;"><tbody><tr><th colspan="2" class="navbox-title" style="text-align:center;font-size:125%;font-weight:bold">Imatinib</th></tr><tr><td colspan="2" style="text-align:center"><i>Drug mechanism</i></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/1IEP.png" tppabs="https://ptable.com/wiki/compounds/I/m/1IEP.png" data-file-width="1600" data-file-height="1200" data-file-type="bitmap" height="173" width="230"></figure-inline><div>Crystallographic structure of tyrosine-protein kinase ABL (rainbow colored, N-terminus = blue, C-terminus = red) complexed with imatinib (spheres, carbon = white, oxygen = red, nitrogen = blue).<span class="mw-ref" id="cite_ref-pmid12154025_27-0"><a href="#cite_note-pmid12154025-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></div></td></tr><tr><th scope="row">Therapeutic use</th><td>chronic myelogenous leukemia</td></tr><tr><th scope="row">Biological target</th><td>ABL, c-kit, PDGF-R</td></tr><tr><th scope="row">Mechanism of action</th><td>Tyrosine-kinase inhibitor</td></tr><tr><th colspan="2" style="text-align:center">External links</th></tr><tr><th scope="row">ATC code</th><td>L01<span class="reflink  nourlexpansion"><a href="javascript:if(confirm('http://www.whocc.no/atc_ddd_index/?code=L01XE01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.whocc.no/atc_ddd_index/?code=L01XE01'" tppabs="http://www.whocc.no/atc_ddd_index/?code=L01XE01" class="external text external">XE01</a></span></td></tr><tr><th scope="row">PDB ligand id</th><td>STI: <small><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/STI  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/STI'" tppabs="http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/STI" class="external text external">PDBe</a></span>, <span class="reflink  nourlexpansion"><a href="javascript:if(confirm('http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=STI  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=STI'" tppabs="http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=STI" class="external text external">RCSB PDB</a></span></small></td></tr><tr><th scope="row">LIGPLOT</th><td><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=1iep&template=ligands.html&l=1.1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=1iep&template=ligands.html&l=1.1'" tppabs="http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=1iep&template=ligands.html&l=1.1" class="external text external">1iep</a></span></td></tr></tbody></table>

<p>Imatinib is a 2-phenyl amino <a href="Pyrimidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrimidine" title="Pyrimidine">pyrimidine</a> derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. It occupies the <i>TK</i> active site, leading to a decrease in activity.</p>

<p>There are a large number of <i>TK</i> enzymes in the body, including the insulin receptor. Imatinib is specific for the <i>TK</i> domain in <i>abl</i> (the Abelson proto-oncogene), c-kit and PDGF-R (platelet-derived growth factor receptor).</p>

<p>In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of <i>abl</i> with <i>bcr</i> (<i>breakpoint cluster region</i>), termed <i>bcr-abl</i>. As this is now a <a href="javascript:if(confirm('https://en.wiktionary.org/wiki/constitutive  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wiktionary.org/wiki/constitutive'" tppabs="https://en.wiktionary.org/wiki/constitutive" title="wikt:constitutive" class="external">constitutively active</a> tyrosine kinase, imatinib is used to decrease <i>bcr-abl</i> activity.</p>

<p>The active sites of tyrosine kinases each have a binding site for <a href="Adenosine_triphosphate.htm" tppabs="https://ptable.com/wiki/compounds/A/Adenosine_triphosphate" title="Adenosine triphosphate">ATP</a>. The enzymatic activity catalyzed by a tyrosine kinase is the transfer of the terminal phosphate from ATP to <a href="Tyrosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyrosine" title="Tyrosine">tyrosine</a> residues on its substrates, a process known as protein tyrosine phosphorylation. Imatinib works by binding close to the ATP binding site of <i>bcr-abl</i>, locking it in a closed or self-inhibited conformation, and therefore inhibiting the enzyme activity of the protein semi-competitively.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> This fact explains why many BCR-ABL mutations can cause resistance to imatinib by shifting its equilibrium toward the open or active conformation.<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span></p>

<p>Imatinib is quite selective for <i>bcr-abl</i>, though it does also inhibit other targets mentioned above (c-kit and PDGF-R), as well as ABL2 (ARG) and DDR1 tyrosine kinases and NQO2 – an oxidoreductase.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> Imatinib also inhibits the <i>abl</i> protein of non-cancer cells, but these cells normally have additional redundant tyrosine kinases, which allows them to continue to function even if <i>abl</i> tyrosine kinase is inhibited. Some tumor cells, however, have a dependence on <i>bcr-abl</i>.<span class="mw-ref" id="cite_ref-DeiningerDruker_31-0"><a href="#cite_note-DeiningerDruker-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> Inhibition of the <i>bcr-abl</i> tyrosine kinase also stimulates its entry in to the nucleus, where it is unable to perform any of its normal anti-apoptopic functions, leading to tumor cell death.<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Other_pathways_affected">Other pathways affected</h3></summary>
    
<p>The Bcr-Abl pathway has many downstream pathways including<span class="mw-ref" id="cite_ref-pmid17457302_33-0"><a href="#cite_note-pmid17457302-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>
<ul><li>the Ras/MapK pathway, which leads to increased proliferation due to increased growth factor-independent cell growth.</li>
<li>It also affects the <span class="new">Src/Pax/Fak/Rac pathway</span>. This affects the cytoskeleton, which leads to increased cell motility and decreased adhesion.</li>
<li>The PI/PI3K/AKT/BCL-2 pathway is also affected. BCL-2 is responsible for keeping the mitochondria stable; this suppresses cell death by apoptosis and increases survival.</li>
<li>The last pathway that Bcr-Abl affects is the JAK/STAT pathway, which is responsible for proliferation.<span class="mw-ref" id="cite_ref-pmid17457302_33-1"><a href="#cite_note-pmid17457302-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></li></ul>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacokinetics">Pharmacokinetics</h2></summary>
    
<p>Imatinib is rapidly absorbed when given by mouth, and is highly bioavailable: 98% of an oral dose reaches the bloodstream. Metabolism of imatinib occurs in the liver and is mediated by several isozymes of the cytochrome P450 system, including CYP3A4 and, to a lesser extent, CYP1A2, CYP2D6, CYP2C9, and CYP2C19. The main metabolite, <i>N</i>-demethylated <a href="Piperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperazine" title="Piperazine">piperazine</a> derivative, is also active. The major route of elimination is in the bile and feces; only a small portion of the drug is excreted in the urine. Most of imatinib is eliminated as metabolites; only 25% is eliminated unchanged. The half-lives of imatinib and its main metabolite are 18 h and 40 h, respectively. It blocks the activity of Abelson cytoplasmic tyrosine kinase (ABL), c-Kit and the platelet-derived growth factor receptor (PDGFR). As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.<span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>Its use is advised against in people on strong CYP3A4 inhibitors such as <a href="Clarithromycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clarithromycin" title="Clarithromycin">clarithromycin</a>, <a href="Chloramphenicol.htm" tppabs="https://ptable.com/wiki/compounds/A/Chloramphenicol" title="Chloramphenicol">chloramphenicol</a>, <a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">ketoconazole</a>, <a href="Ritonavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Ritonavir" title="Ritonavir">ritonavir</a> and <a href="Nefazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nefazodone" title="Nefazodone">nefazodone</a> due to its reliance on CYP3A4 for metabolism.<span class="mw-ref" id="cite_ref-MSR_19-1"><a href="#cite_note-MSR-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Likewise it is a CYP3A4, CYP2D6 and CYP2C9 inhibitor and hence concurrent treatment with substrates of any of these enzymes may increase plasma concentrations of said drugs.<span class="mw-ref" id="cite_ref-MSR_19-2"><a href="#cite_note-MSR-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Since imatinib is mainly metabolised via the liver enzyme CYP3A4, substances influencing the activity of this enzyme change the plasma concentration of the drug. An example of a drug that increases imatinib activity and therefore side effects by blocking CYP3A4 is <a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">ketoconazole</a>. The same could be true of <a href="Itraconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Itraconazole" title="Itraconazole">itraconazole</a>, <a href="Clarithromycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clarithromycin" title="Clarithromycin">clarithromycin</a>, grapefruit juice, among others. Conversely, CYP3A4 inductors like <a href="Rifampicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rifampicin" title="Rifampicin">rifampicin</a> and St John's Wort reduce the drug's activity, risking therapy failure. Imatinib also acts as an inhibitor of CYP3A4, 2C9 and 2D6, increasing the plasma concentrations of a number of other drugs like <a href="Simvastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Simvastatin" title="Simvastatin">simvastatin</a>, <a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">ciclosporin</a>, <a href="Pimozide.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimozide" title="Pimozide">pimozide</a>, <a href="Warfarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Warfarin" title="Warfarin">warfarin</a>, <a href="Metoprolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Metoprolol" title="Metoprolol">metoprolol</a>, and possibly <a href="Paracetamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Paracetamol" title="Paracetamol">paracetamol</a>. The drug also reduces plasma levels of levothyroxin via an unknown mechanism.<span class="mw-ref" id="cite_ref-AustriaCodex_21-1"><a href="#cite_note-AustriaCodex-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>As with other immunosuppressants, application of live vaccines is contraindicated because the microorganisms in the vaccine could multiply and infect the patient. Inactivated and toxoid vaccines do not hold this risk, but may not be effective under imatinib therapy.<span class="mw-ref" id="cite_ref-Arzneimittel-Interaktionen_35-0"><a href="#cite_note-Arzneimittel-Interaktionen-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    

<p>Imatinib was invented in the late 1990s by scientists at Ciba-Geigy (which merged with Sandoz in 1996 to become Novartis), in a team led by biochemist Nicholas Lydon and that included Elisabeth Buchdunger and Jürg Zimmermann<span class="mw-ref" id="cite_ref-Innovation_36-0"><a href="#cite_note-Innovation-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> and its use to treat CML was driven by oncologist Brian Druker of Oregon Health &amp; Science University (OHSU).<span class="mw-ref" id="cite_ref-NYT_20091103_37-0"><a href="#cite_note-NYT_20091103-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> Other major contributions to imatinib development were made by Carlo Gambacorti-Passerini, a physician, scientist, and hematologist at University of Milano Bicocca, Italy, John Goldman at Hammersmith Hospital in London, UK, and later on by Charles Sawyers of Memorial Sloan-Kettering Cancer Center.<span class="mw-ref" id="cite_ref-NYT_20091103_37-1"><a href="#cite_note-NYT_20091103-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span><span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>

<p>Imatinib was developed by rational drug design. After the Philadelphia chromosome mutation and hyperactive <i>bcr-abl</i> protein were discovered, the investigators screened chemical libraries to find a drug that would inhibit that protein. With high-throughput screening, they identified 2-<span class="new">phenylaminopyrimidine</span>. This lead compound was then tested and modified by the introduction of methyl and <a href="Benzamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzamide" title="Benzamide">benzamide</a> groups to give it enhanced binding properties, resulting in imatinib.<span class="mw-ref" id="cite_ref-39"><a href="#cite_note-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>

<p>When Novartis tested imatinib in rats, mice, rabbits, dogs, and monkeys in 1996, it was found to have several toxic effects; in particular, results indicating liver damage in dogs nearly stopped drug development completely. However, favorable results in studies with monkeys and <i>in vitro</i> human cells allowed testing to continue in humans.<span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-Monmaney_1999_41-0"><a href="#cite_note-Monmaney_1999-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-Li_2015_p._81_42-0"><a href="#cite_note-Li_2015_p._81-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>

<p>The first clinical trial of Gleevec took place in 1998, after Novartis reluctantly synthesized and released a few grams of the drug for Druker, enough for him to run a trial using a hundred or so patients.<span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span> The drug received FDA approval in May 2001, only two and a half years after the new drug application was submitted.<span class="mw-ref" id="cite_ref-Innovation_36-1"><a href="#cite_note-Innovation-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span><span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span>  On the same month it made the cover of <i>TIME</i> magazine as a "bullet" to be used against cancer. Druker, Lydon and Sawyers received the Lasker-DeBakey Clinical Medical Research Award in 2009 for "converting a fatal cancer into a manageable chronic condition".<span class="mw-ref" id="cite_ref-NYT_20091103_37-2"><a href="#cite_note-NYT_20091103-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>

<p>During the FDA review, the tradename of the drug for the US market was changed from "Glivec" to "Gleevec" at the request of the FDA, to avoid confusion with <a href="Miglitol.htm" tppabs="https://ptable.com/wiki/compounds/A/Glyset" title="Glyset" class="mw-redirect">Glyset</a>, a diabetes drug.<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span><span class="mw-ref" id="cite_ref-46"><a href="#cite_note-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span><span class="mw-ref" id="cite_ref-47"><a href="#cite_note-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span></p>

<p>A Swiss patent application was filed on imatinib and various salts on in April 1992, which was then filed in the EU, the US, and other countries in March and April 1993.<span class="mw-ref" id="cite_ref-US5521184_48-0"><a href="#cite_note-US5521184-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span><span class="mw-ref" id="cite_ref-Patentfamily_49-0"><a href="#cite_note-Patentfamily-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span> and in 1996 United States and European patent offices issued patents listing Jürg Zimmermann as the inventor.<span class="mw-ref" id="cite_ref-US5521184_48-1"><a href="#cite_note-US5521184-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span><span class="mw-ref" id="cite_ref-EP0564409_50-0"><a href="#cite_note-EP0564409-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span></p>

<p>In July 1997, Novartis filed a new patent application in Switzerland on the beta crystalline form of imatinib mesylate (the mesylate salt of imatinib).  The "beta crystalline form" of the molecule is a specific polymorph of imatinib mesylate; a specific way that the individual molecules pack together to form a solid.  This is the actual form of the drug sold as Gleevec/Glivec;  a salt (imatinib mesylate) as opposed to a free base, and the beta crystalline form as opposed to the alpha or other form.<span class="mw-ref" id="cite_ref-51"><a href="#cite_note-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><sup class="reference" style="white-space:nowrap;">:<span>3 and 4</span></sup>  In 1998, Novartis filed international patent applications claiming priority to the 1997 filing.<span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-PCT_53-0"><a href="#cite_note-PCT-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> A United States patent was granted in 2005.<span class="mw-ref" id="cite_ref-54"><a href="#cite_note-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Costs">Costs</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Glivec_400mg.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Glivec_400mg.jpg" data-file-width="1183" data-file-height="822" data-file-type="bitmap" height="153" width="220"><div class="thumbcaption" style="text-align: left">A box of 400-milligram Glivec tablets (Novartis), as sold in Germany.</div></div></div>

<p>In 2013, more than 100 cancer specialists published a letter in <i>Blood</i> saying that the prices of many new cancer drugs, including imatinib, are so high that people in the United States couldn't afford them, and that the level of prices, and profits, was so high as to be immoral. Signatories of the letter included Brian Druker, Carlo Gambacorti-Passerini, and John Goldman, developers of imatinib.<span class="mw-ref" id="cite_ref-55"><a href="#cite_note-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span><span class="mw-ref" id="cite_ref-56"><a href="#cite_note-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span>  They wrote that in 2001, imatinib was priced at $30,000 a year, which was based on the price of interferon, then the standard treatment, and that at this price Novartis would have recouped its initial development costs in two years.  They wrote that after unexpectedly becoming a blockbuster, Novartis increased the price to $92,000 per year in 2012, with annual revenues of $4.7 billion.  Other physicians have complained about the cost.<span class="mw-ref" id="cite_ref-57"><a href="#cite_note-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span><span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-59"><a href="#cite_note-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span></p>

<p>Drucker himself, who led the clinical studies, never got a patent and never made money from it.<span class="mw-ref" id="cite_ref-60"><a href="#cite_note-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span></p>

<p>By 2016, the average wholesale price had increased to $120,000 a year, according to an analysis prepared for <i>The Washington Post</i> by Stacie Dusetzina of the University of North Carolina at Chapel Hill. When competitive drugs came on the market, they were sold at a higher price to reflect the smaller population, and Novartis raised the price of Gleevec to match them.<span class="mw-ref" id="cite_ref-61"><a href="#cite_note-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span></p>

<p>A 2012 economic analysis funded by Bristol-Myers Squibb estimated that the discovery and development of imatinib and related drugs had created $143 billion in societal value at a cost to consumers of approximately $14 billion.  The $143 billion figure was based on an estimated 7.5 to 17.5 year survival advantage conferred by imatinib treatment, and included the value (discounted at 3% per annum) of ongoing benefits to society after the imatinib patent expiration.<span class="mw-ref" id="cite_ref-62"><a href="#cite_note-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span></p>

<p>Prices for a 100<span>&nbsp;</span>mg pill of Gleevec internationally range from $20 to $30,<span class="mw-ref" id="cite_ref-63"><a href="#cite_note-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span> although generic imatinib is cheaper, as low as $2 per pill.<span class="mw-ref" id="cite_ref-64"><a href="#cite_note-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Patent_litigation_in_India">Patent litigation in India</h3></summary>
    


<p>Novartis fought a seven-year, controversial battle to patent Gleevec in India, and took the case all the way to the Indian Supreme Court.  The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to abide by worldwide intellectual property standards under the TRIPS agreement.  As part of this agreement, India made changes to its patent law, the biggest of which was that prior to these changes, patents on products were not allowed, while afterwards they were, albeit with restrictions.  These changes came into effect in 2005, so Novartis' patent application waited in a "mailbox" with others until then, under procedures that India instituted to manage the transition.  India also passed certain amendments to its patent law in 2005, just before the laws came into effect.<span class="mw-ref" id="cite_ref-NYTreact_65-0"><a href="#cite_note-NYTreact-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span><span class="mw-ref" id="cite_ref-66"><a href="#cite_note-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span></p>

<p>The patent application<span class="mw-ref" id="cite_ref-PCT_53-1"><a href="#cite_note-PCT-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-67"><a href="#cite_note-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span> claimed the final form of Gleevec (the beta crystalline form of imatinib mesylate).<span class="mw-ref" id="cite_ref-68"><a href="#cite_note-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span><sup class="reference" style="white-space:nowrap;">:<span>3</span></sup>  In 1993, during the time India did not allow patents on products, Novartis had patented imatinib, with salts vaguely specified, in many countries but could not patent it in India.<span class="mw-ref" id="cite_ref-US5521184_48-2"><a href="#cite_note-US5521184-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span><span class="mw-ref" id="cite_ref-EP0564409_50-1"><a href="#cite_note-EP0564409-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span>  The key differences between the two patent applications, were that 1998 patent application specified the counterion (Gleevec is a specific salt – imatinib mesylate) while the 1993 patent application did not claim any specific salts nor did it mention mesylate, and the 1998 patent application specified the solid form of Gleevec – the way the individual molecules are packed together into a solid when the drug itself is manufactured (this is separate from processes by which the drug itself is formulated into pills or capsules) – while the 1993 patent application did not.  The solid form of imatinib mesylate in Gleevec is beta crystalline.<span class="mw-ref" id="cite_ref-69"><a href="#cite_note-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p>

<p>As provided under the TRIPS agreement, Novartis applied for Exclusive Marketing Rights (EMR) for Gleevec from the Indian Patent Office and the EMR was granted in November 2003.<span class="mw-ref" id="cite_ref-Decision8-9_70-0"><a href="#cite_note-Decision8-9-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span>  Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India.<span class="mw-ref" id="cite_ref-SpicyIP1_71-0"><a href="#cite_note-SpicyIP1-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-WSJ_72-0"><a href="#cite_note-WSJ-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span></p>

<p>When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy groups.  The application was rejected by the patent office and by an appeal board.  The key basis for the rejection was the part of Indian patent law that was created by amendment in 2005, describing the patentability of new uses for known drugs and modifications of known drugs.  That section, 3d, specified that such inventions are patentable only if "they differ significantly in properties with regard to efficacy."<span class="mw-ref" id="cite_ref-SpicyIP1_71-1"><a href="#cite_note-SpicyIP1-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-Appellate_73-0"><a href="#cite_note-Appellate-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span>    At one point, Novartis went to court to try to invalidate Section 3d; it argued that the provision was unconstitutionally vague and that it violated TRIPS.  Novartis lost that case and did not appeal.<span class="mw-ref" id="cite_ref-2007Decn_74-0"><a href="#cite_note-2007Decn-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> Novartis did appeal the rejection by the patent office to India's Supreme Court, which took the case.</p>

<p>The Supreme Court case hinged on the interpretation of Section 3d.  The Supreme Court issued its decision in 2013, ruling that the substance that Novartis sought to patent was indeed a modification of a known drug (the raw form of imatinib, which was publicly disclosed in the 1993 patent application and in scientific articles), that Novartis did not present evidence of a difference in therapeutic efficacy between the final form of Gleevec and the raw form of imatinib, and that therefore the patent application was properly rejected by the patent office and lower courts.<span class="mw-ref" id="cite_ref-75"><a href="#cite_note-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>One study demonstrated that imatinib mesylate was effective in patients with systemic mastocytosis, including those who had the D816V mutation in c-KIT.<span class="mw-ref" id="cite_ref-76"><a href="#cite_note-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> However, since imatinib binds to tyrosine kinases when they are in the inactive configuration and the D816V mutant of c-KIT is constitutively active, imatinib does not inhibit the kinase activity of the D816V mutant of c-KIT.  Experience has shown, however, that imatinib is much less effective in patients with this mutation, and patients with the mutation comprise nearly 90% of cases of mastocytosis.</p>

<p>Imatinib was initially thought to have a potential role in the treatment of pulmonary hypertension. It was shown to reduce both the smooth muscle hypertrophy and hyperplasia of the pulmonary vasculature in a variety of disease processes, including portopulmonary hypertension.<span class="mw-ref" id="cite_ref-77"><a href="#cite_note-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span> However, a long-term trial of Imatinib in people with pulmonary arterial hypertension was unsuccessful, and serious and unexpected adverse events were frequent. These included 6 subdural hematomas and 17 deaths during or within 30 days of study end.<span class="mw-ref" id="cite_ref-78"><a href="#cite_note-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span></p>

<p>In systemic sclerosis, the drug has been tested for potential use in slowing down pulmonary fibrosis. In laboratory settings, imatinib is being used as an experimental agent to suppress platelet-derived growth factor (PDGF) by inhibiting its receptor (PDGF-Rβ). One of its effects is delaying atherosclerosis in mice without<span class="mw-ref" id="cite_ref-79"><a href="#cite_note-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span> or with diabetes.<span class="mw-ref" id="cite_ref-pmid14988091_80-0"><a href="#cite_note-pmid14988091-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span></p>

<p>Mouse animal studies have suggested that imatinib and related drugs may be useful in treating smallpox, should an outbreak ever occur.<span class="mw-ref" id="cite_ref-pmid15980865_81-0"><a href="#cite_note-pmid15980865-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span></p>

<p><i>In vitro</i> studies identified that a modified version of imatinib can bind to gamma-secretase activating protein (GSAP). GSAP selectively increases the production and accumulation of neurotoxic beta-amyloid plaques, which suggests that molecules which target GSAP and are able to cross blood–brain barrier are potential therapeutic agents for treating Alzheimer's disease.<span class="mw-ref" id="cite_ref-pmid20811458_82-0"><a href="#cite_note-pmid20811458-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> Another study suggests that imatinib may not need to cross the blood–brain barrier to be effective at treating Alzheimer's, as the research indicates the production of beta-amyloid may begin in the liver. Tests on mice indicate that imatinib is effective at reducing beta-amyloid in the brain.<span class="mw-ref" id="cite_ref-83"><a href="#cite_note-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> It is not known whether reduction of beta-amyloid is a feasible way of treating Alzheimer's, as an anti-beta-amyloid vaccine has been shown to clear the brain of plaques without having any effect on Alzheimer symptoms.<span class="mw-ref" id="cite_ref-pmid18640458_84-0"><a href="#cite_note-pmid18640458-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span></p>

<p>A formulation of imatinib with a <a href="Cyclodextrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclodextrin" title="Cyclodextrin">cyclodextrin</a> (<span class="new">Captisol</span>) as a carrier to overcome the blood–brain barrier is also currently considered as an experimental drug for lowering and reversing opioid tolerance. Imatinib has shown reversal of tolerance in rats.<span class="mw-ref" id="cite_ref-85"><a href="#cite_note-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span>
Imatinib is an experimental drug in the treatment of desmoid tumor or aggressive fibromatosis.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Bcr-Abl tyrosine-kinase inhibitor</li>
<li>History of cancer chemotherapy</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/imatinib.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/imatinib.html'" tppabs="https://www.drugs.com/pregnancy/imatinib.html" class="external text external">"Imatinib (Gleevec) Use During Pregnancy"</a>. <i>Drugs.com</i>. 27 August 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">16 February</span> 2020</span>.</cite></span></li><li id="cite_note-AHFS2017-2"> <span id="mw-reference-text-cite_note-AHFS2017-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/imatinib-mesylate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/imatinib-mesylate.html'" tppabs="https://www.drugs.com/monograph/imatinib-mesylate.html" class="external text external">"Imatinib Mesylate"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20170116192526/https://www.drugs.com/monograph/imatinib-mesylate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170116192526/https://www.drugs.com/monograph/imatinib-mesylate.html'" tppabs="https://web.archive.org/web/20170116192526/https://www.drugs.com/monograph/imatinib-mesylate.html" class="external text external">Archived</a> from the original on 16 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">8 January</span> 2017</span>.</cite></span></li><li id="cite_note-WHO21st-3"> <span id="mw-reference-text-cite_note-WHO21st-3" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-ERC2014-4"> <span id="mw-reference-text-cite_note-ERC2014-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf'" tppabs="http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf" class="external text external">"International Drug Price Indicator Guide – 2014 edition"</a> <span class="cs1-format">(PDF)</span>. p.<span>&nbsp;</span>A-57. <a href="javascript:if(confirm('https://web.archive.org/web/20170110144554/http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170110144554/http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf'" tppabs="https://web.archive.org/web/20170110144554/http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 10 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2016</span>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78'" tppabs="https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78" class="external text external">"NADAC as of 2016-12-07"</a>. <i>Centers for Medicare and Medicaid Services</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20161221003023/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161221003023/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78'" tppabs="https://web.archive.org/web/20161221003023/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78" class="external text external">Archived</a> from the original on 21 December 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">12 January</span> 2017</span>.</cite></span></li><li id="cite_note-BNF69-6"> <span id="mw-reference-text-cite_note-BNF69-6" class="mw-reference-text"><cite class="citation book cs1"><i>British national formulary<span>&nbsp;</span>: BNF 69</i> (69 ed.). British Medical Association. 2015. p.<span>&nbsp;</span>616. ISBN<span>&nbsp;</span><bdi>9780857111562</bdi>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://oxfordpharmacystore.co.uk/latest_news/generic-imatinib/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://oxfordpharmacystore.co.uk/latest_news/generic-imatinib/'" tppabs="http://oxfordpharmacystore.co.uk/latest_news/generic-imatinib/" class="external text external">"Oxford Pharmacy Store Generic Imatinib<span>&nbsp;</span>: Oxford Pharmacy Store"</a>. <i>oxfordpharmacystore.co.uk</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20170402081046/http://oxfordpharmacystore.co.uk/latest_news/generic-imatinib/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170402081046/http://oxfordpharmacystore.co.uk/latest_news/generic-imatinib/'" tppabs="https://web.archive.org/web/20170402081046/http://oxfordpharmacystore.co.uk/latest_news/generic-imatinib/" class="external text external">Archived</a> from the original on 2 April 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">1 April</span> 2017</span>.</cite></span></li><li id="cite_note-cancernetwork.com-8"> <span id="mw-reference-text-cite_note-cancernetwork.com-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cancernetwork.com/gastrointestinal-cancer/gleevec-gains-simultaneous-fda-approval-five-rare-life-threatening-disorders  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cancernetwork.com/gastrointestinal-cancer/gleevec-gains-simultaneous-fda-approval-five-rare-life-threatening-disorders'" tppabs="https://www.cancernetwork.com/gastrointestinal-cancer/gleevec-gains-simultaneous-fda-approval-five-rare-life-threatening-disorders" class="external text external">"Gleevec Gains Simultaneous FDA Approval for Five Rare, Life-Threatening Disorders"</a>. <i>Cancer Network</i>. 1 November 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">10 June</span> 2020</span>.</cite></span></li><li id="cite_note-FDA-9"> <span id="mw-reference-text-cite_note-FDA-9" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf" class="external text external">"FDA Highlights and Prescribing Information for Gleevec(imatinib mesylate)"</a> <span class="cs1-format">(PDF)</span>. <a href="javascript:if(confirm('https://web.archive.org/web/20140913120652/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140913120652/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf'" tppabs="https://web.archive.org/web/20140913120652/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 13 September 2014.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics'" tppabs="http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics" class="external text external">"Leukemia – Chronic Myeloid – CML: Statistics <span>|</span> Cancer.Net"</a>. 26 June 2012. <a href="javascript:if(confirm('https://web.archive.org/web/20141112155938/http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20141112155938/http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics'" tppabs="https://web.archive.org/web/20141112155938/http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/statistics" class="external text external">Archived</a> from the original on 12 November 2014.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://seer.cancer.gov/statfacts/html/cmyl.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://seer.cancer.gov/statfacts/html/cmyl.html'" tppabs="https://seer.cancer.gov/statfacts/html/cmyl.html" class="external text external">"Cancer Stat Facts: Leukemia — Chronic Myeloid Leukemia (CML)"</a>. <i>Cancer.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">17 April</span> 2020</span>.</cite></span></li><li id="cite_note-onclive-12"> <span id="mw-reference-text-cite_note-onclive-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.onclive.com/web-exclusives/Prolonged-Use-of-Imatinib-in-GIST-Patients-Leads-to-New-FDA-Approval  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.onclive.com/web-exclusives/Prolonged-Use-of-Imatinib-in-GIST-Patients-Leads-to-New-FDA-Approval'" tppabs="http://www.onclive.com/web-exclusives/Prolonged-Use-of-Imatinib-in-GIST-Patients-Leads-to-New-FDA-Approval" class="external text external">"Prolonged Use of Imatinib in GIST Patients Leads to New FDA Approval"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20120204082247/http://www.onclive.com/web-exclusives/Prolonged-Use-of-Imatinib-in-GIST-Patients-Leads-to-New-FDA-Approval  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120204082247/http://www.onclive.com/web-exclusives/Prolonged-Use-of-Imatinib-in-GIST-Patients-Leads-to-New-FDA-Approval'" tppabs="https://web.archive.org/web/20120204082247/http://www.onclive.com/web-exclusives/Prolonged-Use-of-Imatinib-in-GIST-Patients-Leads-to-New-FDA-Approval" class="external text external">Archived</a> from the original on 4 February 2012.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20130310094645/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130310094645/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm'" tppabs="https://web.archive.org/web/20130310094645/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm" class="external text external">"FDA approves Gleevec for children with acute lymphoblastic leukemia"</a>. <i>FDA News Release</i>. US Food and Drug Administration. 25 January 2013. Archived from <a href="javascript:if(confirm('https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm'" tppabs="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm" class="external text external">the original</a> on 10 March 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">3 April</span> 2013</span>.</cite></span></li><li id="cite_note-pmid18984156-14"> <span id="mw-reference-text-cite_note-pmid18984156-14" class="mw-reference-text"><cite id="CITEREFYangIngramChenZhu2008" class="citation journal cs1">Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, Yu M, Burns D, Robertson K, Hutchins G, Parada LF, Clapp DW (October 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788814  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788814'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788814" class="external text external">"Nf1-dependent tumors require a microenvironment containing Nf1+/--and c-kit-dependent bone marrow"</a>. <i>Cell</i>. <b>135</b> (3): 437–48. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.cell.2008.08.041  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.cell.2008.08.041'" tppabs="https://doi.org/10.1016%2Fj.cell.2008.08.041" class="external text external">10.1016/j.cell.2008.08.041</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788814  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788814'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788814" class="external text external">2788814</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18984156  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18984156'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18984156" class="external text external">18984156</a>. <a href="javascript:if(confirm('https://www.sciencedaily.com/releases/2008/10/081030123837.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sciencedaily.com/releases/2008/10/081030123837.htm'" tppabs="https://www.sciencedaily.com/releases/2008/10/081030123837.htm" class="external text external">Lay summary</a> <span>–</span> <i>Science Daily</i>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120420015449/http://nfcure.org/newnf1trial/gleevecnf1trial.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120420015449/http://nfcure.org/newnf1trial/gleevecnf1trial.html'" tppabs="https://web.archive.org/web/20120420015449/http://nfcure.org/newnf1trial/gleevecnf1trial.html" class="external text external">"Gleevec NF1 Trial"</a>. Nfcure.org. Archived from <a href="javascript:if(confirm('http://www.nfcure.org/newnf1trial/gleevecnf1trial.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nfcure.org/newnf1trial/gleevecnf1trial.html'" tppabs="http://www.nfcure.org/newnf1trial/gleevecnf1trial.html" class="external text external">the original</a> on 20 April 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">3 April</span> 2013</span>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20130329203014/http://www.gistsupport.org/about-gist/gist-in-neurofibromatosis-1.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130329203014/http://www.gistsupport.org/about-gist/gist-in-neurofibromatosis-1.php'" tppabs="https://web.archive.org/web/20130329203014/http://www.gistsupport.org/about-gist/gist-in-neurofibromatosis-1.php" class="external text external">"GIST in Neurofibromatosis 1"</a>. Gistsupport.org. 14 May 2010. Archived from <a href="javascript:if(confirm('http://www.gistsupport.org/about-gist/gist-in-neurofibromatosis-1.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gistsupport.org/about-gist/gist-in-neurofibromatosis-1.php'" tppabs="http://www.gistsupport.org/about-gist/gist-in-neurofibromatosis-1.php" class="external text external">the original</a> on 29 March 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">3 April</span> 2013</span>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://clinicaltrials.gov/ct2/show/NCT01140360  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://clinicaltrials.gov/ct2/show/NCT01140360'" tppabs="http://clinicaltrials.gov/ct2/show/NCT01140360" class="external text external">"<span class="cs1-kern-left">"</span>Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas (0908-09)" (Suspended)"</a>. Clinicaltrials.gov. <a href="javascript:if(confirm('https://web.archive.org/web/20130703202412/http://www.clinicaltrials.gov/ct2/show/NCT01140360  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130703202412/http://www.clinicaltrials.gov/ct2/show/NCT01140360'" tppabs="https://web.archive.org/web/20130703202412/http://www.clinicaltrials.gov/ct2/show/NCT01140360" class="external text external">Archived</a> from the original on 3 July 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">3 April</span> 2013</span>.</cite></span></li><li id="cite_note-EMC-18"> <span id="mw-reference-text-cite_note-EMC-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.medicines.org.uk/emc/medicine/15014/SPC/GLIVEC+Tablets/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicines.org.uk/emc/medicine/15014/SPC/GLIVEC+Tablets/'" tppabs="http://www.medicines.org.uk/emc/medicine/15014/SPC/GLIVEC+Tablets/" class="external text external">"Glivec Tablets – Summary of Product Characteristics (SPC)"</a>. <i>electronic Medicines Compendium</i>. Novartis Pharmaceuticals UK Ltd. <a href="javascript:if(confirm('https://web.archive.org/web/20140201204756/http://www.medicines.org.uk/emc/medicine/15014/SPC/GLIVEC+Tablets/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140201204756/http://www.medicines.org.uk/emc/medicine/15014/SPC/GLIVEC+Tablets/'" tppabs="https://web.archive.org/web/20140201204756/http://www.medicines.org.uk/emc/medicine/15014/SPC/GLIVEC+Tablets/" class="external text external">Archived</a> from the original on 1 February 2014.</cite></span></li><li id="cite_note-MSR-19"> <span id="mw-reference-text-cite_note-MSR-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://reference.medscape.com/drug/gleevec-imatinib-342239  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://reference.medscape.com/drug/gleevec-imatinib-342239#showall'" tppabs="http://reference.medscape.com/drug/gleevec-imatinib-342239#showall" class="external text external">"Gleevec (imatinib) dosing, indications, interactions, adverse effects, and more"</a>. <i>Medscape Reference</i>. WebMD. <a href="javascript:if(confirm('https://web.archive.org/web/20140103224530/http://reference.medscape.com/drug/gleevec-imatinib-342239  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140103224530/http://reference.medscape.com/drug/gleevec-imatinib-342239#showall'" tppabs="https://web.archive.org/web/20140103224530/http://reference.medscape.com/drug/gleevec-imatinib-342239#showall" class="external text external">Archived</a> from the original on 3 January 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">24 January</span> 2014</span>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Biologicaltherapies/Cancergrowthinhibitors/Imatinib.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Biologicaltherapies/Cancergrowthinhibitors/Imatinib.aspx#DynamicJumpMenuManager_6_Anchor_3'" tppabs="http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Biologicaltherapies/Cancergrowthinhibitors/Imatinib.aspx#DynamicJumpMenuManager_6_Anchor_3" class="external text external">"Imatinib"</a>. <i>Macmillan Cancer Support</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20121122103401/http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Biologicaltherapies/Cancergrowthinhibitors/Imatinib.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20121122103401/http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Biologicaltherapies/Cancergrowthinhibitors/Imatinib.aspx#DynamicJumpMenuManager_6_Anchor_3'" tppabs="https://web.archive.org/web/20121122103401/http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Biologicaltherapies/Cancergrowthinhibitors/Imatinib.aspx#DynamicJumpMenuManager_6_Anchor_3" class="external text external">Archived</a> from the original on 22 November 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">26 December</span> 2012</span>.</cite></span></li><li id="cite_note-AustriaCodex-21"> <span id="mw-reference-text-cite_note-AustriaCodex-21" class="mw-reference-text"><cite id="CITEREFHaberfeld,_H2009" class="citation book cs1">Haberfeld, H, ed. (2009). <i>Austria-Codex</i> (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN<span>&nbsp;</span><bdi>978-3-85200-196-8</bdi>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite id="CITEREFAltman2002" class="citation news cs1">Altman, Lawrence K. (8 August 2002). <a href="javascript:if(confirm('https://www.nytimes.com/2002/08/08/us/leukemia-drug-side-effect-color-returned-to-gray-hair.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2002/08/08/us/leukemia-drug-side-effect-color-returned-to-gray-hair.html'" tppabs="https://www.nytimes.com/2002/08/08/us/leukemia-drug-side-effect-color-returned-to-gray-hair.html" class="external text external">"Leukemia Drug Side Effect: Color Returned to Gray Hair"</a>. <i>The New York Times</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20151208140911/http://www.nytimes.com/2002/08/08/us/leukemia-drug-side-effect-color-returned-to-gray-hair.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151208140911/http://www.nytimes.com/2002/08/08/us/leukemia-drug-side-effect-color-returned-to-gray-hair.html'" tppabs="https://web.archive.org/web/20151208140911/http://www.nytimes.com/2002/08/08/us/leukemia-drug-side-effect-color-returned-to-gray-hair.html" class="external text external">Archived</a> from the original on 8 December 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">5 December</span> 2015</span>. <q>In a puzzling and intriguing side effect, a new antileukemia drug has darkened the gray hair of some patients, French doctors reported yesterday.</q></cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://news.bbc.co.uk/2/hi/health/2180244.stm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://news.bbc.co.uk/2/hi/health/2180244.stm'" tppabs="http://news.bbc.co.uk/2/hi/health/2180244.stm" class="external text external">"Cancer drug restores hair colour"</a>. BBC News Online. 8 August 2002. <a href="javascript:if(confirm('https://web.archive.org/web/20150926085325/http://news.bbc.co.uk/2/hi/health/2180244.stm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150926085325/http://news.bbc.co.uk/2/hi/health/2180244.stm'" tppabs="https://web.archive.org/web/20150926085325/http://news.bbc.co.uk/2/hi/health/2180244.stm" class="external text external">Archived</a> from the original on 26 September 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">5 December</span> 2015</span>. <q>A drug developed to treat leukaemia has been found to have surprising side effect - it appears able to restore colour to grey hair.</q></cite></span></li><li id="cite_note-pmid16862153-24"> <span id="mw-reference-text-cite_note-pmid16862153-24" class="mw-reference-text"><cite id="CITEREFKerkeläGrazetteYacobiIliescu2006" class="citation journal cs1">Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T (August 2006). <a href="javascript:if(confirm('http://www.escholarship.org/uc/item/34r245fh  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.escholarship.org/uc/item/34r245fh'" tppabs="http://www.escholarship.org/uc/item/34r245fh" class="external text external">"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate"</a>. <i>Nat. Med</i>. <b>12</b> (8): 908–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnm1446  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnm1446'" tppabs="https://doi.org/10.1038%2Fnm1446" class="external text external">10.1038/nm1446</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16862153  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16862153'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16862153" class="external text external">16862153</a>.</cite></span></li><li id="cite_note-pmid21592517-25"> <span id="mw-reference-text-cite_note-pmid21592517-25" class="mw-reference-text"><cite id="CITEREFShimaTokuyamaTanizawaTono2011" class="citation journal cs1">Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, Watanabe A, Hotta N, Ito M, Kurosawa H, Kato K, Tsurusawa M, Horibe K, Shimada H (October 2011). "Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia". <i>J. Pediatr</i>. <b>159</b> (4): 676–81. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jpeds.2011.03.046  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jpeds.2011.03.046'" tppabs="https://doi.org/10.1016%2Fj.jpeds.2011.03.046" class="external text external">10.1016/j.jpeds.2011.03.046</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21592517  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21592517'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21592517" class="external text external">21592517</a>.</cite></span></li><li id="cite_note-TGA-26"> <span id="mw-reference-text-cite_note-TGA-26" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04296-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04296-3'" tppabs="https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04296-3" class="external text external">"Glivec (imatinib)"</a> <span class="cs1-format">(PDF)</span>. <i>TGA eBusiness Services</i>. Novartis Pharmaceuticals Australia Pty Ltd. 21 August 2013. <a href="javascript:if(confirm('https://web.archive.org/web/20170112064341/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04296-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170112064341/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04296-3'" tppabs="https://web.archive.org/web/20170112064341/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04296-3" class="external text external">Archived</a> from the original on 12 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">24 January</span> 2014</span>.</cite></span></li><li id="cite_note-pmid12154025-27"> <span id="mw-reference-text-cite_note-pmid12154025-27" class="mw-reference-text"><span class="">PDB: <a href="javascript:if(confirm('https://www.rcsb.org/structure/1IEP  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.rcsb.org/structure/1IEP'" tppabs="https://www.rcsb.org/structure/1IEP" class="external text external">1IEP</a></span><span>​</span>; <cite id="CITEREFNagarBornmannPellicenaSchindler2002" class="citation journal cs1">Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (August 2002). <a href="javascript:if(confirm('http://cancerres.aacrjournals.org/content/62/15/4236.full.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://cancerres.aacrjournals.org/content/62/15/4236.full.pdf'" tppabs="http://cancerres.aacrjournals.org/content/62/15/4236.full.pdf" class="external text external">"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)"</a> <span class="cs1-format">(PDF)</span>. <i>Cancer Res</i>. <b>62</b> (15): 4236–43. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12154025  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12154025'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12154025" class="external text external">12154025</a>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text">Takimoto CH, Calvo E. <a href="javascript:if(confirm('http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628'" tppabs="http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628" class="external text external">"Principles of Oncologic Pharmacotherapy"</a> <a href="javascript:if(confirm('https://web.archive.org/web/20090515221337/http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090515221337/http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628'" tppabs="https://web.archive.org/web/20090515221337/http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628" class="external text external">Archived</a><span> 15 May 2009 at the </span>Wayback Machine in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds)<a href="javascript:if(confirm('http://www.cancernetwork.com/cancer-management-11/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancernetwork.com/cancer-management-11/'" tppabs="http://www.cancernetwork.com/cancer-management-11/" class="external text external">Cancer Management: A Multidisciplinary Approach</a> <a href="javascript:if(confirm('https://web.archive.org/web/20131004224102/http://www.cancernetwork.com/cancer-management-11/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131004224102/http://www.cancernetwork.com/cancer-management-11/'" tppabs="https://web.archive.org/web/20131004224102/http://www.cancernetwork.com/cancer-management-11/" class="external text external">Archived</a><span> 4 October 2013 at the </span>Wayback Machine. 11 ed. 2008.</span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite id="CITEREFGambacorti-PasseriniGunbyPiazzaGalietta2003" class="citation journal cs1">Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L (February 2003). "Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias". <i>Lancet Oncol</i>. <b>4</b> (2): 75–85. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1470-2045%2803%2900979-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1470-2045%2803%2900979-3'" tppabs="https://doi.org/10.1016%2FS1470-2045%2803%2900979-3" class="external text external">10.1016/S1470-2045(03)00979-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12573349  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12573349'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12573349" class="external text external">12573349</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite id="CITEREFHantschelRixSuperti-Furga2008" class="citation journal cs1">Hantschel, Oliver; Rix, Uwe; Superti-Furga, Giulio (1 January 2008). "Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib". <i>Leukemia &amp; Lymphoma</i>. <b>49</b> (4): 615–619. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F10428190801896103  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F10428190801896103'" tppabs="https://doi.org/10.1080%2F10428190801896103" class="external text external">10.1080/10428190801896103</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1042-8194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1042-8194'" tppabs="https://www.worldcat.org/issn/1042-8194" class="external text external">1042-8194</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18398720  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18398720'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18398720" class="external text external">18398720</a>.</cite></span></li><li id="cite_note-DeiningerDruker-31"> <span id="mw-reference-text-cite_note-DeiningerDruker-31" class="mw-reference-text"><cite id="CITEREFDeiningerDruker2003" class="citation journal cs1">Deininger MW, Druker BJ (September 2003). <a href="javascript:if(confirm('https://semanticscholar.org/paper/218befc2c4e6a115003dd37908762daf71cd9ec2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/218befc2c4e6a115003dd37908762daf71cd9ec2'" tppabs="https://semanticscholar.org/paper/218befc2c4e6a115003dd37908762daf71cd9ec2" class="external text external">"Specific targeted therapy of chronic myelogenous leukemia with imatinib"</a>. <i>Pharmacol. Rev</i>. <b>55</b> (3): 401–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1124%2Fpr.55.3.4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1124%2Fpr.55.3.4'" tppabs="https://doi.org/10.1124%2Fpr.55.3.4" class="external text external">10.1124/pr.55.3.4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12869662  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12869662'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12869662" class="external text external">12869662</a>.</cite></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite id="CITEREFVigneriWang2001" class="citation journal cs1">Vigneri P, Wang JY (February 2001). "Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase". <i>Nat. Med</i>. <b>7</b> (2): 228–34. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2F84683  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F84683'" tppabs="https://doi.org/10.1038%2F84683" class="external text external">10.1038/84683</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11175855  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11175855'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11175855" class="external text external">11175855</a>.</cite></span></li><li id="cite_note-pmid17457302-33"> <span id="mw-reference-text-cite_note-pmid17457302-33" class="mw-reference-text"><cite id="CITEREFWeisbergManleyCowan-JacobHochhaus2007" class="citation journal cs1">Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (May 2007). "Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia". <i>Nature Reviews Cancer</i>. <b>7</b> (5): 345–56. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnrc2126  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnrc2126'" tppabs="https://doi.org/10.1038%2Fnrc2126" class="external text external">10.1038/nrc2126</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17457302  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17457302'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17457302" class="external text external">17457302</a>.</cite></span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite id="CITEREFScheinfeldSchienfeld2006" class="citation journal cs1">Scheinfeld N, Schienfeld N (February 2006). "A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases". <i>J Drugs Dermatol</i>. <b>5</b> (2): 117–22. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16485879  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16485879'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16485879" class="external text external">16485879</a>.</cite></span></li><li id="cite_note-Arzneimittel-Interaktionen-35"> <span id="mw-reference-text-cite_note-Arzneimittel-Interaktionen-35" class="mw-reference-text"><cite id="CITEREFKlopp,_T2010" class="citation book cs1">Klopp, T, ed. (2010). <i>Arzneimittel-Interaktionen</i> (in German) (2010/2011 ed.). Arbeitsgemeinschaft für Pharmazeutische Information. ISBN<span>&nbsp;</span><bdi>978-3-85200-207-1</bdi>.</cite></span></li><li id="cite_note-Innovation-36"> <span id="mw-reference-text-cite_note-Innovation-36" class="mw-reference-text">Staff, Innovation.org (a project of the Pharmaceutical Research and Manufacturers of America)<a href="javascript:if(confirm('http://www.innovation.org/index.cfm/StoriesofInnovation/InnovatorStories/The_Story_of_Gleevec  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.innovation.org/index.cfm/StoriesofInnovation/InnovatorStories/The_Story_of_Gleevec'" tppabs="http://www.innovation.org/index.cfm/StoriesofInnovation/InnovatorStories/The_Story_of_Gleevec" class="external text external">The Story of Gleevec</a> <a href="javascript:if(confirm('https://web.archive.org/web/20131021011042/http://www.innovation.org/index.cfm/StoriesofInnovation/InnovatorStories/The_Story_of_Gleevec  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131021011042/http://www.innovation.org/index.cfm/StoriesofInnovation/InnovatorStories/The_Story_of_Gleevec'" tppabs="https://web.archive.org/web/20131021011042/http://www.innovation.org/index.cfm/StoriesofInnovation/InnovatorStories/The_Story_of_Gleevec" class="external text external">Archived</a><span> 21 October 2013 at the </span>Wayback Machine</span></li><li id="cite_note-NYT_20091103-37"> <span id="mw-reference-text-cite_note-NYT_20091103-37" class="mw-reference-text"><cite id="CITEREFDreifus2009" class="citation news cs1">Dreifus, Claudia (2 November 2009). <a href="javascript:if(confirm('https://www.nytimes.com/2009/11/03/science/03conv.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2009/11/03/science/03conv.html'" tppabs="https://www.nytimes.com/2009/11/03/science/03conv.html" class="external text external">"Researcher Behind the Drug Gleevec"</a>. <i>The New York Times</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20140114055940/http://www.nytimes.com/2009/11/03/science/03conv.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140114055940/http://www.nytimes.com/2009/11/03/science/03conv.html'" tppabs="https://web.archive.org/web/20140114055940/http://www.nytimes.com/2009/11/03/science/03conv.html" class="external text external">Archived</a> from the original on 14 January 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">16 February</span> 2020</span>.</cite></span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text"><cite id="CITEREFGambacorti-Passerini2008" class="citation journal cs1">Gambacorti-Passerini C (June 2008). "Part I: Milestones in personalised medicine--imatinib". <i>Lancet Oncology</i>. <b>9</b> (6): 600. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1470-2045%2808%2970152-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1470-2045%2808%2970152-9'" tppabs="https://doi.org/10.1016%2FS1470-2045%2808%2970152-9" class="external text external">10.1016/S1470-2045(08)70152-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18510992  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18510992'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18510992" class="external text external">18510992</a>.</cite></span></li><li id="cite_note-39"> <span id="mw-reference-text-cite_note-39" class="mw-reference-text"><cite id="CITEREFDrukerLydon2000" class="citation journal cs1">Druker BJ, Lydon NB (January 2000). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC382593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC382593'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC382593" class="external text external">"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia"</a>. <i>J. Clin. Invest</i>. <b>105</b> (1): 3–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1172%2FJCI9083  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1172%2FJCI9083'" tppabs="https://doi.org/10.1172%2FJCI9083" class="external text external">10.1172/JCI9083</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC382593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC382593'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC382593" class="external text external">382593</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10619854  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10619854'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10619854" class="external text external">10619854</a>.</cite></span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text"><cite id="CITEREFPippin2012" class="citation journal cs1">Pippin, J. J. (2012). <a href="javascript:if(confirm('http://animalstudiesrepository.org/cgi/viewcontent.cgi?article=1013&context=acwp_all  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://animalstudiesrepository.org/cgi/viewcontent.cgi?article=1013&context=acwp_all'" tppabs="http://animalstudiesrepository.org/cgi/viewcontent.cgi?article=1013&context=acwp_all" class="external text external">"Animal research in medical sciences: Seeking a convergence of science, medicine, and animal law"</a>. <i>S. Tex. L. Rev</i>. <b>54</b>: 469. <a href="javascript:if(confirm('https://web.archive.org/web/20170918185556/http://animalstudiesrepository.org/cgi/viewcontent.cgi?article=1013&context=acwp_all  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170918185556/http://animalstudiesrepository.org/cgi/viewcontent.cgi?article=1013&context=acwp_all'" tppabs="https://web.archive.org/web/20170918185556/http://animalstudiesrepository.org/cgi/viewcontent.cgi?article=1013&context=acwp_all" class="external text external">Archived</a> from the original on 18 September 2017.</cite>.</span></li><li id="cite_note-Monmaney_1999-41"> <span id="mw-reference-text-cite_note-Monmaney_1999-41" class="mw-reference-text"><cite id="CITEREFMonmaney1999" class="citation web cs1">Monmaney, Terence (3 December 1999). <a href="javascript:if(confirm('http://www.smithsonianmag.com/science-nature/a-triumph-in-the-war-against-cancer-1784705/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.smithsonianmag.com/science-nature/a-triumph-in-the-war-against-cancer-1784705/'" tppabs="http://www.smithsonianmag.com/science-nature/a-triumph-in-the-war-against-cancer-1784705/" class="external text external">"A Triumph in the War Against Cancer"</a>. <i>Smithsonian</i><span class="reference-accessdate">. Retrieved <span class="nowrap">16 January</span> 2017</span>.</cite></span></li><li id="cite_note-Li_2015_p._81-42"> <span id="mw-reference-text-cite_note-Li_2015_p._81-42" class="mw-reference-text"><cite id="CITEREFLi2015" class="citation book cs1">Li, J.J. (2015). <a href="javascript:if(confirm('https://books.google.com/books?id=Dq3fCQAAQBAJ&pg=PA81  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Dq3fCQAAQBAJ&pg=PA81'" tppabs="https://books.google.com/books?id=Dq3fCQAAQBAJ&pg=PA81" class="external text external"><i>Top Drugs: History, Pharmacology, Syntheses</i></a>. Oxford University Press. p.<span>&nbsp;</span>81. ISBN<span>&nbsp;</span><bdi>978-0-19-936259-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170918185556/https://books.google.com/books?id=Dq3fCQAAQBAJ&pg=PA81  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170918185556/https://books.google.com/books?id=Dq3fCQAAQBAJ&pg=PA81'" tppabs="https://web.archive.org/web/20170918185556/https://books.google.com/books?id=Dq3fCQAAQBAJ&pg=PA81" class="external text external">Archived</a> from the original on 18 September 2017.</cite></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite id="CITEREFSiddhartha2010" class="citation book cs1">Siddhartha, Mukherjee (2010). <span class="cs1-lock-registration"><a href="javascript:if(confirm('https://archive.org/details/emperorofallmala00mukh/page/436  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/emperorofallmala00mukh/page/436'" tppabs="https://archive.org/details/emperorofallmala00mukh/page/436" class="external text external"><i>The Emperor of All Maladies</i></a></span>. New York, NY: Scribner. pp.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/emperorofallmala00mukh/page/436  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/emperorofallmala00mukh/page/436'" tppabs="https://archive.org/details/emperorofallmala00mukh/page/436" class="external text external">436</a>. ISBN<span>&nbsp;</span><bdi>978-1-4391-0795-9</bdi>.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text">Novartis press release, 10 May 2001.  <a href="javascript:if(confirm('http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=5838  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=5838'" tppabs="http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=5838" class="external text external">FDA approves Novartis' unique cancer medication Glivec</a></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text">Cohen MH et al. <a href="javascript:if(confirm('http://clincancerres.aacrjournals.org/content/8/5/935.long  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://clincancerres.aacrjournals.org/content/8/5/935.long'" tppabs="http://clincancerres.aacrjournals.org/content/8/5/935.long" class="external text external">Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia</a> <a href="javascript:if(confirm('https://web.archive.org/web/20120719012128/http://clincancerres.aacrjournals.org/content/8/5/935.long  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120719012128/http://clincancerres.aacrjournals.org/content/8/5/935.long'" tppabs="https://web.archive.org/web/20120719012128/http://clincancerres.aacrjournals.org/content/8/5/935.long" class="external text external">Archived</a><span> 19 July 2012 at the </span>Wayback Machine Clin Cancer Res May 2002 8; 935</span></li><li id="cite_note-46"> <span id="mw-reference-text-cite_note-46" class="mw-reference-text">Margot J. Fromer for Oncology Times.  December 2002. <a href="javascript:if(confirm('http://www.brandinstitute.com/NEWS/ONCOLOGYTIMES_12_02.HTM  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.brandinstitute.com/NEWS/ONCOLOGYTIMES_12_02.HTM'" tppabs="http://www.brandinstitute.com/NEWS/ONCOLOGYTIMES_12_02.HTM" class="external text external">What's in a Name?  Quite a Lot When It Comes to Marketing &amp; Selling New Cancer Drugs</a> <a href="javascript:if(confirm('https://web.archive.org/web/20131021122531/http://www.brandinstitute.com/NEWS/ONCOLOGYTIMES_12_02.HTM  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131021122531/http://www.brandinstitute.com/NEWS/ONCOLOGYTIMES_12_02.HTM'" tppabs="https://web.archive.org/web/20131021122531/http://www.brandinstitute.com/NEWS/ONCOLOGYTIMES_12_02.HTM" class="external text external">Archived</a><span> 21 October 2013 at the </span>Wayback Machine</span></li><li id="cite_note-47"> <span id="mw-reference-text-cite_note-47" class="mw-reference-text">Novartis Press Release. 30 April 2001 <a href="javascript:if(confirm('http://www.thefreelibrary.com/Novartis+Oncology+Changes+Trade+Name+of+Investigational+Agent...-a073818775  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.thefreelibrary.com/Novartis+Oncology+Changes+Trade+Name+of+Investigational+Agent...-a073818775'" tppabs="http://www.thefreelibrary.com/Novartis+Oncology+Changes+Trade+Name+of+Investigational+Agent...-a073818775" class="external text external">Novartis Oncology Changes Trade Name of Investigational Agent Glivec to Gleevec in the United States</a></span></li><li id="cite_note-US5521184-48"> <span id="mw-reference-text-cite_note-US5521184-48" class="mw-reference-text"><span><a href="javascript:if(confirm('https://www.google.com/patents/US5521184  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.google.com/patents/US5521184'" tppabs="https://www.google.com/patents/US5521184" class="external text external">U.S. Patent 5,521,184</a></span></span></li><li id="cite_note-Patentfamily-49"> <span id="mw-reference-text-cite_note-Patentfamily-49" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://worldwide.espacenet.com/publicationDetails/inpadocPatentFamily?CC=US&NR=5521184A&KC=A&FT=D&ND=3&date=19960528&DB=worldwide.espacenet.com&locale=en_EP  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://worldwide.espacenet.com/publicationDetails/inpadocPatentFamily?CC=US&NR=5521184A&KC=A&FT=D&ND=3&date=19960528&DB=worldwide.espacenet.com&locale=en_EP'" tppabs="http://worldwide.espacenet.com/publicationDetails/inpadocPatentFamily?CC=US&NR=5521184A&KC=A&FT=D&ND=3&date=19960528&DB=worldwide.espacenet.com&locale=en_EP" class="external text external">"Imatinib Patent Family"</a>. Espacenet. 1996<span class="reference-accessdate">. Retrieved <span class="nowrap">23 July</span> 2014</span>.</cite></span></li><li id="cite_note-EP0564409-50"> <span id="mw-reference-text-cite_note-EP0564409-50" class="mw-reference-text"><span class="citation patent"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=EP0564409  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=EP0564409'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=EP0564409" class="external text external">EP 0564409</a></span></span></li><li id="cite_note-51"> <span id="mw-reference-text-cite_note-51" class="mw-reference-text">Staff, European Medicines Agency, 2004.<a href="javascript:if(confirm('http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf'" tppabs="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf" class="external text external">EMEA Scientific Discussion of Glivec</a> <a href="javascript:if(confirm('https://web.archive.org/web/20141105064353/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20141105064353/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf'" tppabs="https://web.archive.org/web/20141105064353/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf" class="external text external">Archived</a><span> 5 November 2014 at the </span>Wayback Machine</span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text">Note:  The Indian patent application, which became the subject of litigation in India that gathered a lot of press, does not appear to be publicly available.  However according to <a href="javascript:if(confirm('https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India'" tppabs="https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India" class="external text external">documents produced in the course of that litigation</a> <a href="javascript:if(confirm('https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India'" tppabs="https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India" class="external text external">Archived</a><span> 16 July 2015 at the </span>Wayback Machine (page 27), "The Appellant's application under the PCT was substantially on the same invention as had been made in India."</span></li><li id="cite_note-PCT-53"> <span id="mw-reference-text-cite_note-PCT-53" class="mw-reference-text"><span class="citation patent"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO9903854  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO9903854'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=WO9903854" class="external text external">WO 9903854</a></span></span></li><li id="cite_note-54"> <span id="mw-reference-text-cite_note-54" class="mw-reference-text"><span><a href="javascript:if(confirm('https://www.google.com/patents/US6894051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.google.com/patents/US6894051'" tppabs="https://www.google.com/patents/US6894051" class="external text external">U.S. Patent 6,894,051</a></span></span></li><li id="cite_note-55"> <span id="mw-reference-text-cite_note-55" class="mw-reference-text"><cite id="CITEREFExperts_in_Chronic_Myeloid_Leukemia2013" class="citation journal cs1">Experts in Chronic Myeloid Leukemia (May 2013). <a href="javascript:if(confirm('http://bloodjournal.hematologylibrary.org/content/early/2013/04/23/blood-2013-03-490003.full.pdf+html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://bloodjournal.hematologylibrary.org/content/early/2013/04/23/blood-2013-03-490003.full.pdf+html'" tppabs="http://bloodjournal.hematologylibrary.org/content/early/2013/04/23/blood-2013-03-490003.full.pdf+html" class="external text external">"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts"</a>. <i>Blood</i>. <b>121</b> (22): 4439–42. doi:<a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood-2013-03-490003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood-2013-03-490003'" tppabs="https://doi.org/10.1182%2Fblood-2013-03-490003" class="external text external">10.1182/blood-2013-03-490003</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190613'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190613" class="external text external">4190613</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23620577  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23620577'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23620577" class="external text external">23620577</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20140326114400/http://bloodjournal.hematologylibrary.org/content/early/2013/04/23/blood-2013-03-490003.full.pdf+html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140326114400/http://bloodjournal.hematologylibrary.org/content/early/2013/04/23/blood-2013-03-490003.full.pdf+html'" tppabs="https://web.archive.org/web/20140326114400/http://bloodjournal.hematologylibrary.org/content/early/2013/04/23/blood-2013-03-490003.full.pdf+html" class="external text external">Archived</a> from the original on 26 March 2014.</cite></span></li><li id="cite_note-56"> <span id="mw-reference-text-cite_note-56" class="mw-reference-text"><cite id="CITEREFPollack2013" class="citation news cs1">Pollack, Andrew (25 April 2013). <a href="javascript:if(confirm('https://web.archive.org/web/20170221195459/http://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170221195459/http://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html'" tppabs="https://web.archive.org/web/20170221195459/http://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html" class="external text external">"Doctors Denounce Cancer Drug Prices of $100,000 a Year"</a>. <i>The New York Times</i>. Archived from <a href="javascript:if(confirm('https://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html'" tppabs="https://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html" class="external text external">the original</a> on 21 February 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">16 February</span> 2020</span>.</cite></span></li><li id="cite_note-57"> <span id="mw-reference-text-cite_note-57" class="mw-reference-text"><cite id="CITEREFSchiffer_CA2007" class="citation journal cs1">Schiffer CA (July 2007). "BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia". <i>N. Engl. J. Med</i>. <b>357</b> (3): 258–65. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMct071828  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMct071828'" tppabs="https://doi.org/10.1056%2FNEJMct071828" class="external text external">10.1056/NEJMct071828</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17634461  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17634461'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17634461" class="external text external">17634461</a>.</cite></span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text"><cite id="CITEREFPollack2009" class="citation news cs1">Pollack, Andrew (14 April 2009). <a href="javascript:if(confirm('https://web.archive.org/web/20141102215810/http://www.nytimes.com/2009/04/15/business/15pill.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20141102215810/http://www.nytimes.com/2009/04/15/business/15pill.html'" tppabs="https://web.archive.org/web/20141102215810/http://www.nytimes.com/2009/04/15/business/15pill.html" class="external text external">"As Pills Treat Cancer, Insurance Lags Behind"</a>. <i>The New York Times</i>. Archived from <a href="javascript:if(confirm('https://www.nytimes.com/2009/04/15/business/15pill.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2009/04/15/business/15pill.html'" tppabs="https://www.nytimes.com/2009/04/15/business/15pill.html" class="external text external">the original</a> on 2 November 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">16 February</span> 2020</span>.</cite></span></li><li id="cite_note-59"> <span id="mw-reference-text-cite_note-59" class="mw-reference-text"><cite id="CITEREFBrody2010" class="citation news cs1">Brody, Jane E. (18 January 2010). <a href="javascript:if(confirm('https://web.archive.org/web/20170209082505/http://www.nytimes.com/2010/01/19/health/19brod.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170209082505/http://www.nytimes.com/2010/01/19/health/19brod.html'" tppabs="https://web.archive.org/web/20170209082505/http://www.nytimes.com/2010/01/19/health/19brod.html" class="external text external">"Living With a Formerly Fatal Blood Cancer"</a>. <i>The New York Times</i>. Archived from <a href="javascript:if(confirm('https://www.nytimes.com/2010/01/19/health/19brod.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2010/01/19/health/19brod.html'" tppabs="https://www.nytimes.com/2010/01/19/health/19brod.html" class="external text external">the original</a> on 9 February 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">16 February</span> 2020</span>.</cite></span></li><li id="cite_note-60"> <span id="mw-reference-text-cite_note-60" class="mw-reference-text"><cite id="CITEREFRosenthal2018" class="citation news cs1">Rosenthal, Elisabeth (21 June 2018). <a href="javascript:if(confirm('https://www.nytimes.com/2018/06/21/opinion/competition-drug-prices.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2018/06/21/opinion/competition-drug-prices.html'" tppabs="https://www.nytimes.com/2018/06/21/opinion/competition-drug-prices.html" class="external text external">"Why Competition Won't Bring Down Drug Prices"</a>. <i>The New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">16 February</span> 2020</span>.</cite></span></li><li id="cite_note-61"> <span id="mw-reference-text-cite_note-61" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html'" tppabs="https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html" class="external text external">"This drug is defying a rare form of leukemia — and it keeps getting pricier"</a>. <i>The Washington Post</i>. 9 March 2016. <a href="javascript:if(confirm('https://web.archive.org/web/20160310135532/https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160310135532/https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html'" tppabs="https://web.archive.org/web/20160310135532/https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html" class="external text external">Archived</a> from the original on 10 March 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">10 March</span> 2016</span>.</cite></span></li><li id="cite_note-62"> <span id="mw-reference-text-cite_note-62" class="mw-reference-text"><cite id="CITEREFYinPenrodMacleanLakdawalla2012" class="citation journal cs1">Yin W, Penrod JR, Maclean R, Lakdawalla DN, Philipson T (November 2012). <a href="javascript:if(confirm('http://www.ajmc.com/journals/supplement/2012/A386_12nov_Oncology/A386_12nov_Onclogy_Yin_S257to64/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ajmc.com/journals/supplement/2012/A386_12nov_Oncology/A386_12nov_Onclogy_Yin_S257to64/'" tppabs="http://www.ajmc.com/journals/supplement/2012/A386_12nov_Oncology/A386_12nov_Onclogy_Yin_S257to64/" class="external text external">"Value of survival gains in chronic myeloid leukemia"</a>. <i>Am J Manag Care</i>. <b>18</b> (11 Suppl): S257–64. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23327457  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23327457'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23327457" class="external text external">23327457</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20150724000812/http://www.ajmc.com/journals/supplement/2012/A386_12nov_Oncology/A386_12nov_Onclogy_Yin_S257to64/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150724000812/http://www.ajmc.com/journals/supplement/2012/A386_12nov_Oncology/A386_12nov_Onclogy_Yin_S257to64/'" tppabs="https://web.archive.org/web/20150724000812/http://www.ajmc.com/journals/supplement/2012/A386_12nov_Oncology/A386_12nov_Onclogy_Yin_S257to64/" class="external text external">Archived</a> from the original on 24 July 2015.</cite></span></li><li id="cite_note-63"> <span id="mw-reference-text-cite_note-63" class="mw-reference-text"><a href="javascript:if(confirm('http://www.pmprb-cepmb.gc.ca/english/View.asp?x=529&mp=572  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pmprb-cepmb.gc.ca/english/View.asp?x=529&mp=572'" tppabs="http://www.pmprb-cepmb.gc.ca/english/View.asp?x=529&mp=572" class="external text external">Patented Medicine Review Board (Canada).</a> <a href="javascript:if(confirm('https://web.archive.org/web/20110706181917/http://www.pmprb-cepmb.gc.ca/english/View.asp?x=529&mp=572  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110706181917/http://www.pmprb-cepmb.gc.ca/english/View.asp?x=529&mp=572'" tppabs="https://web.archive.org/web/20110706181917/http://www.pmprb-cepmb.gc.ca/english/View.asp?x=529&mp=572" class="external text external">Archived</a><span> 6 July 2011 at the </span>Wayback Machine Report on New Patented Drugs – Gleevec.</span></li><li id="cite_note-64"> <span id="mw-reference-text-cite_note-64" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.pharmacychecker.com/listing.asp?criteria_2=imatinib&Search=1&x=51&y=14  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pharmacychecker.com/listing.asp?criteria_2=imatinib&Search=1&x=51&y=14'" tppabs="http://www.pharmacychecker.com/listing.asp?criteria_2=imatinib&Search=1&x=51&y=14" class="external text external">"pharmacychecker.com"</a>. pharmacychecker.com. <a href="javascript:if(confirm('https://web.archive.org/web/20140202125936/http://www.pharmacychecker.com/listing.asp?criteria_2=imatinib&Search=1&x=51&y=14  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140202125936/http://www.pharmacychecker.com/listing.asp?criteria_2=imatinib&Search=1&x=51&y=14'" tppabs="https://web.archive.org/web/20140202125936/http://www.pharmacychecker.com/listing.asp?criteria_2=imatinib&Search=1&x=51&y=14" class="external text external">Archived</a> from the original on 2 February 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">3 April</span> 2013</span>.</cite></span></li><li id="cite_note-NYTreact-65"> <span id="mw-reference-text-cite_note-NYTreact-65" class="mw-reference-text"><cite id="CITEREFHarrisThomas2013" class="citation news cs1">Harris, Gardiner; Thomas, Katie (1 April 2013). <a href="javascript:if(confirm('https://web.archive.org/web/20141220194654/http://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20141220194654/http://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html'" tppabs="https://web.archive.org/web/20141220194654/http://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html" class="external text external">"Low-Cost Drugs in Poor Nations Get a Lift in Indian Court"</a>. <i>The New York Times</i>. Archived from <a href="javascript:if(confirm('https://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html'" tppabs="https://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html" class="external text external">the original</a> on 20 December 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">16 February</span> 2020</span>.</cite></span></li><li id="cite_note-66"> <span id="mw-reference-text-cite_note-66" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://india.blogs.nytimes.com/2013/04/01/the-novartis-patent-case-the-full-supreme-court-ruling/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://india.blogs.nytimes.com/2013/04/01/the-novartis-patent-case-the-full-supreme-court-ruling/'" tppabs="https://india.blogs.nytimes.com/2013/04/01/the-novartis-patent-case-the-full-supreme-court-ruling/" class="external text external">"The Novartis Patent Case: The Full Supreme Court Ruling"</a>. <i>The New York Times</i>. 1 April 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">16 February</span> 2020</span>.</cite></span></li><li id="cite_note-67"> <span id="mw-reference-text-cite_note-67" class="mw-reference-text">Note:  The Indian patent application No.1602/MAS/1998 does not appear to be publicly available.  However according to <a href="javascript:if(confirm('https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India'" tppabs="https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India" class="external text external">the decision of the IPAB on 26 June 2009</a> <a href="javascript:if(confirm('https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India'" tppabs="https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India" class="external text external">Archived</a><span> 16 July 2015 at the </span>Wayback Machine (page 27) discussed below, "The Appellant's application under the PCT was substantially on the same invention as had been made in India."</span></li><li id="cite_note-68"> <span id="mw-reference-text-cite_note-68" class="mw-reference-text">Staff, European Medicines Agency, 2004. <a href="javascript:if(confirm('http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf'" tppabs="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf" class="external text external">EMEA Scientific Discussion of Glivec</a> <a href="javascript:if(confirm('https://web.archive.org/web/20141105064353/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20141105064353/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf'" tppabs="https://web.archive.org/web/20141105064353/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf" class="external text external">Archived</a><span> 5 November 2014 at the </span>Wayback Machine</span></li><li id="cite_note-69"> <span id="mw-reference-text-cite_note-69" class="mw-reference-text"><a href="javascript:if(confirm('http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212'" tppabs="http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212" class="external text external">Indian Supreme Court Decision</a> <a href="javascript:if(confirm('https://web.archive.org/web/20130706085312/http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130706085312/http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212'" tppabs="https://web.archive.org/web/20130706085312/http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212" class="external text external">Archived</a><span> 6 July 2013 at the </span>Wayback Machine paragraphs 5–6</span></li><li id="cite_note-Decision8-9-70"> <span id="mw-reference-text-cite_note-Decision8-9-70" class="mw-reference-text"><a href="javascript:if(confirm('http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212'" tppabs="http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212" class="external text external">Novartis v UoI, para 8–9</a> <a href="javascript:if(confirm('https://web.archive.org/web/20130706085312/http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130706085312/http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212'" tppabs="https://web.archive.org/web/20130706085312/http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212" class="external text external">Archived</a><span> 6 July 2013 at the </span>Wayback Machine</span></li><li id="cite_note-SpicyIP1-71"> <span id="mw-reference-text-cite_note-SpicyIP1-71" class="mw-reference-text">Shamnad Basheer for Spicy IP 11 March 2006 <a href="javascript:if(confirm('http://spicyip.com/2006/03/first-mailbox-opposition-gleevec.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://spicyip.com/2006/03/first-mailbox-opposition-gleevec.html'" tppabs="http://spicyip.com/2006/03/first-mailbox-opposition-gleevec.html" class="external text external">First Mailbox Opposition (Gleevec) Decided in India</a> <a href="javascript:if(confirm('https://web.archive.org/web/20131021162820/http://spicyip.com/2006/03/first-mailbox-opposition-gleevec.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131021162820/http://spicyip.com/2006/03/first-mailbox-opposition-gleevec.html'" tppabs="https://web.archive.org/web/20131021162820/http://spicyip.com/2006/03/first-mailbox-opposition-gleevec.html" class="external text external">Archived</a><span> 21 October 2013 at the </span>Wayback Machine</span></li><li id="cite_note-WSJ-72"> <span id="mw-reference-text-cite_note-WSJ-72" class="mw-reference-text">R. Jai Krishna and Jeanne Whalen for the <i>Wall Street Journal</i>. 1 April 2013 <a href="javascript:if(confirm('https://www.wsj.com/news/articles/SB10001424127887323296504578395672582230106  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.wsj.com/news/articles/SB10001424127887323296504578395672582230106'" tppabs="https://www.wsj.com/news/articles/SB10001424127887323296504578395672582230106" class="external text external">Novartis Loses Glivec Patent Battle in India</a> <a href="javascript:if(confirm('https://web.archive.org/web/20160529152242/http://www.wsj.com/news/articles/SB10001424127887323296504578395672582230106  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160529152242/http://www.wsj.com/news/articles/SB10001424127887323296504578395672582230106'" tppabs="https://web.archive.org/web/20160529152242/http://www.wsj.com/news/articles/SB10001424127887323296504578395672582230106" class="external text external">Archived</a><span> 29 May 2016 at the </span>Wayback Machine</span></li><li id="cite_note-Appellate-73"> <span id="mw-reference-text-cite_note-Appellate-73" class="mw-reference-text"><a href="javascript:if(confirm('https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India'" tppabs="https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India" class="external text external">Intellectual Property Appellate Board decision dated 26 June 2009, p 149</a> <a href="javascript:if(confirm('https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India'" tppabs="https://web.archive.org/web/20150716041227/https://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India" class="external text external">Archived</a><span> 16 July 2015 at the </span>Wayback Machine</span></li><li id="cite_note-2007Decn-74"> <span id="mw-reference-text-cite_note-2007Decn-74" class="mw-reference-text"><a href="javascript:if(confirm('http://judis.nic.in/judis_chennai/qrydispfree.aspx?filename=11121  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://judis.nic.in/judis_chennai/qrydispfree.aspx?filename=11121'" tppabs="http://judis.nic.in/judis_chennai/qrydispfree.aspx?filename=11121" class="external text external">W.P. No.24759 of 2006</a> <a href="javascript:if(confirm('https://web.archive.org/web/20131020071414/http://judis.nic.in/judis_chennai/qrydispfree.aspx?filename=11121  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131020071414/http://judis.nic.in/judis_chennai/qrydispfree.aspx?filename=11121'" tppabs="https://web.archive.org/web/20131020071414/http://judis.nic.in/judis_chennai/qrydispfree.aspx?filename=11121" class="external text external">Archived</a><span> 20 October 2013 at the </span>Wayback Machine</span></li><li id="cite_note-75"> <span id="mw-reference-text-cite_note-75" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://spicyipindia.blogspot.co.uk/2013/04/supreme-court-rejects-bid-by-novartis.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://spicyipindia.blogspot.co.uk/2013/04/supreme-court-rejects-bid-by-novartis.html'" tppabs="http://spicyipindia.blogspot.co.uk/2013/04/supreme-court-rejects-bid-by-novartis.html" class="external text external">"Supreme Court rejects bid by Novartis to patent Glivec"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20131217091420/http://spicyipindia.blogspot.co.uk/2013/04/supreme-court-rejects-bid-by-novartis.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131217091420/http://spicyipindia.blogspot.co.uk/2013/04/supreme-court-rejects-bid-by-novartis.html'" tppabs="https://web.archive.org/web/20131217091420/http://spicyipindia.blogspot.co.uk/2013/04/supreme-court-rejects-bid-by-novartis.html" class="external text external">Archived</a> from the original on 17 December 2013.</cite></span></li><li id="cite_note-76"> <span id="mw-reference-text-cite_note-76" class="mw-reference-text"><cite id="CITEREFDroogendijkKluin-Nelemansvan_DoormaalOranje2006" class="citation journal cs1">Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL (July 2006). "Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial". <i>Cancer</i>. <b>107</b> (2): 345–51. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fcncr.21996  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fcncr.21996'" tppabs="https://doi.org/10.1002%2Fcncr.21996" class="external text external">10.1002/cncr.21996</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16779792  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16779792'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16779792" class="external text external">16779792</a>.</cite></span></li><li id="cite_note-77"> <span id="mw-reference-text-cite_note-77" class="mw-reference-text"><cite id="CITEREFTapperKnowlesHeffronLawrence2009" class="citation journal cs1">Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M (June 2009). "Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition". <i>Transplant. Proc</i>. <b>41</b> (5): 1969–71. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.transproceed.2009.02.100  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.transproceed.2009.02.100'" tppabs="https://doi.org/10.1016%2Fj.transproceed.2009.02.100" class="external text external">10.1016/j.transproceed.2009.02.100</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19545770  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19545770'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19545770" class="external text external">19545770</a>.</cite></span></li><li id="cite_note-78"> <span id="mw-reference-text-cite_note-78" class="mw-reference-text"><cite id="CITEREFFrostBarstHoeperChang2015" class="citation journal cs1">Frost, Adaani E.; Barst, Robyn J.; Hoeper, Marius M.; Chang, Hyuk-Jae; Frantz, Robert P.; Fukumoto, Yoshihiro; Galié, Nazzareno; Hassoun, Paul M.; Klose, Hans (2015). <a href="javascript:if(confirm('https://doi.org/10.1016/j.healun.2015.05.025  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.healun.2015.05.025'" tppabs="https://doi.org/10.1016/j.healun.2015.05.025" class="external text external">"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension"</a>. <i>The Journal of Heart and Lung Transplantation</i>. <b>34</b> (11): 1366–1375. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.healun.2015.05.025  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.healun.2015.05.025'" tppabs="https://doi.org/10.1016%2Fj.healun.2015.05.025" class="external text external">10.1016/j.healun.2015.05.025</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26210752  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26210752'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26210752" class="external text external">26210752</a>.</cite></span></li><li id="cite_note-79"> <span id="mw-reference-text-cite_note-79" class="mw-reference-text"><cite id="CITEREFBoucherGotthardtLiAnderson2003" class="citation journal cs1">Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J (April 2003). "LRP: role in vascular wall integrity and protection from atherosclerosis". <i>Science</i>. <b>300</b> (5617): 329–32. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2003Sci...300..329B  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2003Sci...300..329B'" tppabs="https://ui.adsabs.harvard.edu/abs/2003Sci...300..329B" class="external text external">2003Sci...300..329B</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.1082095  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.1082095'" tppabs="https://doi.org/10.1126%2Fscience.1082095" class="external text external">10.1126/science.1082095</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12690199  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12690199'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12690199" class="external text external">12690199</a>.</cite></span></li><li id="cite_note-pmid14988091-80"> <span id="mw-reference-text-cite_note-pmid14988091-80" class="mw-reference-text"><cite id="CITEREFLassilaAllenCaoThallas2004" class="citation journal cs1">Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME (May 2004). <a href="javascript:if(confirm('https://doi.org/10.1161/01.ATV.0000124105.39900.db  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161/01.ATV.0000124105.39900.db'" tppabs="https://doi.org/10.1161/01.ATV.0000124105.39900.db" class="external text external">"Imatinib attenuates diabetes-associated atherosclerosis"</a>. <i>Arterioscler. Thromb. Vasc. Biol</i>. <b>24</b> (5): 935–42. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1161%2F01.ATV.0000124105.39900.db  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161%2F01.ATV.0000124105.39900.db'" tppabs="https://doi.org/10.1161%2F01.ATV.0000124105.39900.db" class="external text external">10.1161/01.ATV.0000124105.39900.db</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14988091  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14988091'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14988091" class="external text external">14988091</a>.</cite></span></li><li id="cite_note-pmid15980865-81"> <span id="mw-reference-text-cite_note-pmid15980865-81" class="mw-reference-text"><cite id="CITEREFReevesBommariusLebeisMcNulty2005" class="citation journal cs1">Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D (July 2005). "Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases". <i>Nat. Med</i>. <b>11</b> (7): 731–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnm1265  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnm1265'" tppabs="https://doi.org/10.1038%2Fnm1265" class="external text external">10.1038/nm1265</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15980865  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15980865'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15980865" class="external text external">15980865</a>.</cite></span></li><li id="cite_note-pmid20811458-82"> <span id="mw-reference-text-cite_note-pmid20811458-82" class="mw-reference-text"><cite id="CITEREFHeLuoLiRemmers2010" class="citation journal cs1">He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, Flajolet M, Gorelick F, Wennogle LP, Greengard P (September 2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936959  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936959'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936959" class="external text external">"Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease"</a>. <i>Nature</i>. <b>467</b> (7311): 95–8. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2010Natur.467...95H  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2010Natur.467...95H'" tppabs="https://ui.adsabs.harvard.edu/abs/2010Natur.467...95H" class="external text external">2010Natur.467...95H</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnature09325  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnature09325'" tppabs="https://doi.org/10.1038%2Fnature09325" class="external text external">10.1038/nature09325</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936959  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936959'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936959" class="external text external">2936959</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20811458  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20811458'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20811458" class="external text external">20811458</a>.</cite></span></li><li id="cite_note-83"> <span id="mw-reference-text-cite_note-83" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nbcnews.com/id/41971124  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nbcnews.com/id/41971124'" tppabs="http://www.nbcnews.com/id/41971124" class="external text external">"Alzheimer's may start in liver – Health – Alzheimer's Disease <span>|</span> NBC News"</a>. NBC News. 8 March 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">6 January</span> 2013</span>.</cite></span></li><li id="cite_note-pmid18640458-84"> <span id="mw-reference-text-cite_note-pmid18640458-84" class="mw-reference-text"><cite id="CITEREFHolmesBocheWilkinsonYadegarfar2008" class="citation journal cs1">Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (July 2008). "Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial". <i>Lancet</i>. <b>372</b> (9634): 216–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2808%2961075-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2808%2961075-2'" tppabs="https://doi.org/10.1016%2FS0140-6736%2808%2961075-2" class="external text external">10.1016/S0140-6736(08)61075-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18640458  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18640458'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18640458" class="external text external">18640458</a>.</cite></span></li><li id="cite_note-85"> <span id="mw-reference-text-cite_note-85" class="mw-reference-text"><a href="javascript:if(confirm('http://www.medicalnewstoday.com/articles/242064.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicalnewstoday.com/articles/242064.php'" tppabs="http://www.medicalnewstoday.com/articles/242064.php" class="external text external">Eliminating Morphine Tolerance – Reformulated Imatinib</a> <a href="javascript:if(confirm('https://web.archive.org/web/20130329203539/http://www.medicalnewstoday.com/articles/242064.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130329203539/http://www.medicalnewstoday.com/articles/242064.php'" tppabs="https://web.archive.org/web/20130329203539/http://www.medicalnewstoday.com/articles/242064.php" class="external text external">Archived</a><span> 29 March 2013 at the </span>Wayback Machine 23 Feb 2012, 5:00 PST</span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/imatinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/imatinib'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/imatinib" class="external text external">"Imatinib"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/imatinib%20mesylate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/imatinib%20mesylate'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/imatinib%20mesylate" class="external text external">"Imatinib mesylate"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate'" tppabs="https://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate" class="external text external">"Imatinib mesylate"</a>. <i>National Cancer Institute</i>.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Growth_factor_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Growth_factor_receptor_modulators" style="font-size:114%;margin:0 4em">Growth factor receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Angiopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Angiopoietin 1</li>
<li>Angiopoietin 4</li></ul>

<ul><li><i>Antagonists:</i> Angiopoietin 2</li>
<li><span class="new">Angiopoietin 3</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">CE-245677</span></li>
<li>Rebastinib</li></ul>

<ul><li><i>Antibodies:</i> Evinacumab (against angiopoietin 3)</li>
<li>Nesvacumab (against angiopoietin 2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CNTF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Axokine</li>
<li>CNTF</li>
<li><span class="new">Dapiclermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF (ErbB)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF<br><small>(ErbB1/HER1)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Amphiregulin</li>
<li>Betacellulin</li>
<li>EGF (urogastrone)</li>
<li>Epigen</li>
<li>Epiregulin</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Murodermin</li>
<li>Nepidermin</li>
<li>Transforming growth factor alpha (TGFα)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><span class="new">Agerafenib</span></li>
<li>Brigatinib</li>
<li>Canertinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Grandinin</li>
<li>Icotinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li>
<li>Osimertinib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> <a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><span class="new">Depatuxizumab</span></li>
<li>Depatuxizumab mafodotin</li>
<li>Futuximab</li>
<li>Imgatuzumab</li>
<li>Matuzumab</li>
<li>Necitumumab</li>
<li>Nimotuzumab</li>
<li>Panitumumab</li>
<li>Zalutumumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB2/HER2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: <i>Unknown/none</i></li></ul>

<ul><li><i>Antibodies:</i> Ertumaxomab</li>
<li>Pertuzumab</li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a></li>
<li><span class="new">Trastuzumab duocarmazine</span></li>
<li>Trastuzumab emtansine</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Mubritinib</li>
<li>Neratinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB3/HER3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))</li></ul>

<ul><li><i>Antibodies:</i> Duligotumab</li>
<li>Patritumab</li>
<li>Seribantumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB4/HER4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Betacellulin</li>
<li>Epigen</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Neuregulins (heregulins) (1, 2, 3, 4, <span class="new">5 (tomoregulin, TMEFF)</span>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)</li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Trafermin</li>
<li><span class="new">Velafermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)</li>
<li><a href="Palifermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Palifermin" title="Palifermin">Palifermin</a></li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Aprutumab</span></li>
<li><span class="new">Aprutumab ixadotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)</li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> Burosumab (against FGF23)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)</li>
<li>Trafermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> FGF15/19</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">HGF (c-Met)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Hepatocyte growth factor</li></ul>

<ul><li><i>Potentiators:</i> Dihexa (PNB-0408)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AM7</span></li>
<li><span class="new">AMG-458</span></li>
<li><span class="new">Amuvatinib</span></li>
<li><span class="new">BMS-777607</span></li>
<li>Cabozantinib</li>
<li>Crizotinib</li>
<li>Foretinib</li>
<li><span class="new">Golvatinib</span></li>
<li><span class="new">INCB28060</span></li>
<li><span class="new">JNJ-38877605</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li><span class="new">MK-2461</span></li>
<li><span class="new">PF-04217903</span></li>
<li><span class="new">PF-2341066</span></li>
<li><span class="new">PHA-665752</span></li>
<li><span class="new">SU-11274</span></li>
<li>Tivantinib</li>
<li>Volitinib</li></ul>

<ul><li><i>Antibodies:</i> Emibetuzumab</li>
<li>Ficlatuzumab</li>
<li>Flanvotumab</li>
<li>Onartuzumab</li>
<li>Rilotumumab</li>
<li><span class="new">Telisotuzumab</span></li>
<li><span class="new">Telisotuzumab vedotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: des(1-3)IGF-1</li>
<li>Insulin-like growth factor-1 (somatomedin C)</li>
<li>IGF-1 LR3</li>
<li>Insulin-like growth factor-2 (somatomedin A)</li>
<li><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulin</a></li>
<li><a href="Mecasermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li>Mecasermin rinfabate</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">BMS-754807</span></li>
<li>Linsitinib</li>
<li><span class="new">NVP-ADW742</span></li>
<li><span class="new">NVP-AEW541</span></li>
<li><span class="new">OSl-906</span></li></ul>

<ul><li><i>Antibodies:</i> <span class="new">AVE-1642</span></li>
<li>Cixutumumab</li>
<li>Dalotuzumab</li>
<li>Figitumumab</li>
<li>Ganitumab</li>
<li>Robatumumab</li>
<li><span class="new">R1507</span></li>
<li>Teprotumumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Insulin-like growth factor-2 (somatomedin A)</li></ul>

<ul><li><i>Antibodies:</i> Dusigitumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Binding proteins:</i> IGFBP (1, 2, 3, 4, 5, 6, 7)</li></ul>

<ul><li><i>Cleavage products/derivatives with unknown target:</i> <span class="new">Glypromate (GPE, (1-3)IGF-1)</span></li>
<li>Trofinetide</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">LNGF (p75<sup>NTR</sup>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BDNF</li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li>NGF</li>
<li>NT-3</li>
<li>NT-4</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><span class="new">EVT-901 (SAR-127963)</span></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Antibodies:</i> <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">LEVI-04 (p75<sup>NTR</sup>-Fc)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PDGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Becaplermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Becaplermin" title="Becaplermin">Becaplermin</a></li>
<li>Platelet-derived growth factor (A, B, C, D)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li>Crenolanib</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Lenvatinib</li>
<li>Masitinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Radotinib</li>
<li>Quizartinib</li>
<li>Ripretinib</li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li>Toceranib</li></ul>

<ul><li><i>Antibodies:</i> Olaratumab</li>
<li>Ramucirumab</li>
<li>Tovetumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">RET (GFL)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Glial cell line-derived neurotrophic factor (GDNF)</li>
<li><span class="new">Liatermin</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurturin (NRTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Artemin (ARTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα4</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Persephin (PSPN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Ancestim</li>
<li>Stem cell factor</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Masitinib</li>
<li>Nilotinib</li>
<li>Pazopanib</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Trk</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkA</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><span class="new">Gambogic amide</span></li>
<li>NGF</li>
<li>Tavilermide</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li>FX007</li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Negative allosteric modulators:</i> <span class="new">VM-902A</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">Milciclib</span></li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li>
<li>Rebastinib</li>
<li><span class="new">SNA-120 (pegylated K252a)</span>)</li></ul>

<ul><li><i>Antibodies:</i> <i>Against TrkA:</i> <span class="new">GBR-900</span>; <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">ReN-1820 (TrkAd5)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkB</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">3,7-DHF</span></li>
<li><span class="new">3,7,8,2'-THF</span></li>
<li>4'-DMA-7,8-DHF</li>
<li><span class="new">7,3'-DHF</span></li>
<li>7,8-DHF</li>
<li><span class="new">7,8,2'-THF</span></li>
<li>7,8,3'-THF</li>
<li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BDNF</li>
<li>BNN-20</li>
<li>Deoxygedunin</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Deprenyl" title="Deprenyl" class="mw-redirect">Deprenyl</a></li>
<li>Diosmetin</li>
<li><span class="new">DMAQ-B1</span></li>
<li>HIOC</li>
<li>LM22A-4</li>
<li><a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li>
<li>NT-3</li>
<li>NT-4</li>
<li>Norwogonin (5,7,8-THF)</li>
<li>R7</li>
<li>R13</li>
<li><span class="new">TDP6</span></li></ul>

<ul><li><i>Antagonists:</i> ANA-12</li>
<li>Cyclotraxin B</li>
<li>Gossypetin (3,5,7,8,3',4'-HHF)</li></ul>

<ul><li><i>Ligands:</i> <a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkC</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BNN-20</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li>NT-3</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VEGF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Placental growth factor (PGF)</li>
<li>Ripretinib</li>
<li><span class="new">Telbermin</span></li>
<li>VEGF (A, B, C, D (FIGF))</li></ul>

<ul><li><i>Allosteric modulators:</i> Cyclotraxin B</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li><span class="new">Altiratinib</span></li>
<li>Axitinib</li>
<li>Cabozantinib</li>
<li>Cediranib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Lenvatinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Pegaptanib</li>
<li>Rebastinib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li>
<li>Tivozanib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> Alacizumab pegol</li>
<li>Bevacizumab</li>
<li>Icrucumab</li>
<li>Ramucirumab</li>
<li><a href="Ranibizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranibizumab" title="Ranibizumab">Ranibizumab</a></li></ul>

<ul><li><i>Decoy receptors:</i> Aflibercept</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional growth factors:</i> Adrenomedullin</li>
<li>Colony-stimulating factors (see here instead)</li>
<li>Connective tissue growth factor (CTGF)</li>
<li>Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)</li>
<li>Erythropoietin (see here instead)</li>
<li>Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)</li>
<li>Glia maturation factor (GMF)</li>
<li>Hepatoma-derived growth factor (HDGF)</li>
<li>Interleukins/T-cell growth factors (see here instead)</li>
<li>Leukemia inhibitory factor (LIF)</li>
<li>Macrophage-stimulating protein (MSP; HLP, HGFLP)</li>
<li>Midkine (NEGF2)</li>
<li>Migration-stimulating factor (MSF; PRG4)</li>
<li>Oncomodulin</li>
<li>Pituitary adenylate cyclase-activating peptide (PACAP)</li>
<li>Pleiotrophin</li>
<li>Renalase</li>
<li>Thrombopoietin (see here instead)</li>
<li>Wnt signaling proteins</li></ul>

<ul><li><i>Additional growth factor receptor modulators:</i> Cerebrolysin (neurotrophin mixture)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Piperazines" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Piperazines" style="font-size:114%;margin:0 4em"><a href="Piperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperazine" title="Piperazine">Piperazines</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Simple piperazines<br><small>(no additional rings)</small></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>1-Cyclohexylpiperazine</li>
<li><a href="Aminoethylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoethylpiperazine" title="Aminoethylpiperazine">Aminoethylpiperazine</a></li>
<li><a href="Diethylcarbamazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylcarbamazine" title="Diethylcarbamazine">Diethylcarbamazine</a></li>
<li>HEPPS</li>
<li>Midafotel</li>
<li><a href="Piperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperazine" title="Piperazine">Piperazine</a></li>
<li>PIPES</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Phenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylpiperazine" title="Phenylpiperazine">Phenylpiperazines</a></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>2C-B-PP</li>
<li>3,4-CFP</li>
<li>Acaprazine</li>
<li><a href="Antrafenine.htm" tppabs="https://ptable.com/wiki/compounds/A/Antrafenine" title="Antrafenine">Antrafenine</a></li>
<li><a href="Aripiprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Aripiprazole" title="Aripiprazole">Aripiprazole</a></li>
<li>Batoprazine</li>
<li>Bifeprunox</li>
<li>BRL-15,572</li>
<li>Ciprofloxacin</li>
<li>CSP-2503</li>
<li><a href="Dapiprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dapiprazole" title="Dapiprazole">Dapiprazole</a></li>
<li>DCPP</li>
<li>DMPP</li>
<li>Diphenylpiperazine</li>
<li><a href="Dropropizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dropropizine" title="Dropropizine">Dropropizine</a></li>
<li>EGIS-12,233</li>
<li>Elopiprazole</li>
<li>Eltoprazine</li>
<li>Enpiprazole</li>
<li>Ensaculin</li>
<li>Etoperidone</li>
<li>Flesinoxan</li>
<li>Fluanisone</li>
<li>Flibanserin</li>
<li>Fluprazine</li>
<li><a href="Itraconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Itraconazole" title="Itraconazole">Itraconazole</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li>Levodropropizine</li>
<li>Lorpiprazole</li>
<li><a href="Meta-Chlorophenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meta-Chlorophenylpiperazine" title="Meta-Chlorophenylpiperazine">mCPP</a></li>
<li>Mefway</li>
<li>MeOPP</li>
<li>Mepiprazole</li>
<li><a href="Naftopidil.htm" tppabs="https://ptable.com/wiki/compounds/A/Naftopidil" title="Naftopidil">Naftopidil</a></li>
<li>Naluzotan</li>
<li>Naphthylpiperazine</li>
<li><a href="Nefazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nefazodone" title="Nefazodone">Nefazodone</a></li>
<li>Niaprazine</li>
<li>Oxypertine</li>
<li>Pardoprunox</li>
<li><a href="Para-Chlorophenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Para-Chlorophenylpiperazine" title="Para-Chlorophenylpiperazine">pCPP</a></li>
<li>pFPP</li>
<li><a href="Posaconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Posaconazole" title="Posaconazole">Posaconazole</a></li>
<li>S-14,506</li>
<li>S-14,671</li>
<li>S-15,535</li>
<li>SB-258,585</li>
<li>SB-271,046</li>
<li>SB-357,134</li>
<li>SB-399,885</li>
<li>Sonepiprazole</li>
<li>TFMPP</li>
<li>Tolpiprazole</li>
<li><a href="Trazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Trazodone" title="Trazodone">Trazodone</a></li>
<li>Urapidil</li>
<li>Vesnarinone</li>
<li>Vilazodone</li>
<li>Vortioxetine</li>
<li>WAY-100,135</li>
<li>WAY-100,635</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Benzylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzylpiperazine" title="Benzylpiperazine">Benzylpiperazines</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>2C-B-BZP</li>
<li>3-Methylbenzylpiperazine</li>
<li>Befuraline</li>
<li>Bifeprunox</li>
<li><a href="Buclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Buclizine" title="Buclizine">Buclizine</a></li>
<li><a href="Benzylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzylpiperazine" title="Benzylpiperazine">BZP</a></li>
<li>Chlorbenzoxamine</li>
<li>DBZP</li>
<li>Fipexide</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>MBZP</li>
<li>MDBZP</li>
<li><a href="Meclozine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meclozine" title="Meclozine" class="mw-redirect">Meclozine</a></li>
<li>Methoxypiperamide</li>
<li>Piberaline</li>
<li>Piribedil</li>
<li>Sunifiram</li>
<li>Trimetazidine</li>
<li>Vesnarinone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Diphenylmethylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenylmethylpiperazine" title="Diphenylmethylpiperazine">Diphenylalkylpiperazines</a><br><small>(benzhydrylalkylpiperazines)</small></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>AD-1211</li>
<li><a href="Almitrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Almitrine" title="Almitrine">Almitrine</a></li>
<li>Amperozide</li>
<li>BRL-15,572</li>
<li><a href="Buclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Buclizine" title="Buclizine">Buclizine</a></li>
<li>BW373U86</li>
<li><a href="Cetirizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetirizine" title="Cetirizine">Cetirizine</a></li>
<li>Chlorbenzoxamine</li>
<li><a href="Chlorcyclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorcyclizine" title="Chlorcyclizine">Chlorcyclizine</a></li>
<li><a href="Cinnarizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cinnarizine" title="Cinnarizine">Cinnarizine</a></li>
<li>Clocinizine</li>
<li><a href="Cyclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclizine" title="Cyclizine">Cyclizine</a></li>
<li>DBL-583</li>
<li>Diphenpipenol</li>
<li><a href="Diphenylmethylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenylmethylpiperazine" title="Diphenylmethylpiperazine">Diphenylmethylpiperazine</a></li>
<li>Dotarizine</li>
<li>DPI-221</li>
<li>DPI-287</li>
<li>DPI-3290</li>
<li><span class="new">GBR-12,783</span></li>
<li>GBR-12,935</li>
<li><span class="new">GBR-13,069</span></li>
<li><span class="new">GBR-13,098</span></li>
<li><span class="new">GBR-13,119</span></li>
<li><a href="Hydroxyzine.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroxyzine" title="Hydroxyzine">Hydroxyzine</a></li>
<li><a href="Lidoflazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lidoflazine" title="Lidoflazine">Lidoflazine</a></li>
<li>Manidipine</li>
<li><a href="Meclozine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meclozine" title="Meclozine" class="mw-redirect">Meclozine</a></li>
<li>MT-45</li>
<li><a href="Oxatomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxatomide" title="Oxatomide">Oxatomide</a></li>
<li>SNC-80</li>
<li><a href="Vanoxerine.htm" tppabs="https://ptable.com/wiki/compounds/A/Vanoxerine" title="Vanoxerine">Vanoxerine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Pyrimidinylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrimidinylpiperazine" title="Pyrimidinylpiperazine">Pyrimidinylpiperazines</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Buspirone.htm" tppabs="https://ptable.com/wiki/compounds/A/Buspirone" title="Buspirone">Buspirone</a></li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li>Eptapirone</li>
<li>Gepirone</li>
<li>Ipsapirone</li>
<li>Piribedil</li>
<li>Prazitone</li>
<li><a href="Pyrimidinylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrimidinylpiperazine" title="Pyrimidinylpiperazine">Pyrimidinylpiperazine</a></li>
<li>Revospirone</li>
<li>Tandospirone</li>
<li>Tirilazad</li>
<li>Trimazosin</li>
<li>Umespirone</li>
<li>Zalospirone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Pyridinylpiperazines</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atevirdine</li>
<li>Azaperone</li>
<li><a href="Delavirdine.htm" tppabs="https://ptable.com/wiki/compounds/A/Delavirdine" title="Delavirdine">Delavirdine</a></li>
<li><a href="Mirtazapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mirtazapine" title="Mirtazapine">Mirtazapine</a></li>
<li>Pyridinylpiperazine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Benzothiazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzothiazole" title="Benzothiazole">Benzo(iso)thiazolyl</a><a href="Piperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperazine" title="Piperazine">piperazines</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Lurasidone</li>
<li>Perospirone</li>
<li>Revospirone</li>
<li>Tiospirone</li>
<li><a href="Ziprasidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ziprasidone" title="Ziprasidone">Ziprasidone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tricyclics<br><small>(piperazine attached via side chain)</small></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amoxapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amoxapine" title="Amoxapine">Amoxapine</a></li>
<li>Clopenthixol</li>
<li>Clorotepine</li>
<li><a href="Clozapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clozapine" title="Clozapine">Clozapine</a></li>
<li><span class="new">Cyanothepin</span></li>
<li><span class="new">Doclothepin</span></li>
<li><span class="new">Docloxythepin</span></li>
<li><a href="Flupentixol.htm" tppabs="https://ptable.com/wiki/compounds/A/Flupentixol" title="Flupentixol">Flupentixol</a></li>
<li><a href="Fluphenazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluphenazine" title="Fluphenazine">Fluphenazine</a></li>
<li><span class="new">Isofloxythepin</span></li>
<li><a href="Loxapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Loxapine" title="Loxapine">Loxapine</a></li>
<li><span class="new">Meperathiepin</span></li>
<li>Metitepine</li>
<li><span class="new">Octomethothepin</span></li>
<li><a href="Olanzapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Olanzapine" title="Olanzapine">Olanzapine</a></li>
<li>Opipramol</li>
<li><span class="new">Oxyclothepin</span></li>
<li><span class="new">Oxyprothepin</span></li>
<li><span class="new">Peradithiepin</span></li>
<li>Perathiepin</li>
<li>Perazine</li>
<li><a href="Perphenazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Perphenazine" title="Perphenazine">Perphenazine</a></li>
<li><a href="Pirenzepine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pirenzepine" title="Pirenzepine">Pirenzepine</a></li>
<li><a href="Prochlorperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prochlorperazine" title="Prochlorperazine">Prochlorperazine</a></li>
<li><a href="Thiethylperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiethylperazine" title="Thiethylperazine">Thiethylperazine</a></li>
<li><a href="Thiothixene.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiothixene" title="Thiothixene" class="mw-redirect">Thiothixene</a></li>
<li><a href="Trifluoperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a></li>
<li><span class="new">Trifluthepin</span></li>
<li><a href="Zuclopenthixol.htm" tppabs="https://ptable.com/wiki/compounds/A/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others/Uncategorized</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>6-Nitroquipazine</li>
<li>Azimilide</li>
<li>Cinepazet</li>
<li>Cinepazic acid</li>
<li>Cinepazide</li>
<li>Cyclohexylpiperazine</li>
<li>EGIS-7625</li>
<li>Hexocyclium</li>
<li><a href="Indinavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Indinavir" title="Indinavir">Indinavir</a></li>
<li>JNJ-7777120</li>
<li>Lodenafil</li>
<li>Mirodenafil</li>
<li>PB-28</li>
<li>Quipazine</li>
<li><a href="Ranolazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranolazine" title="Ranolazine">Ranolazine</a></li>
<li>SA-4503</li>
<li><a href="Sildenafil.htm" tppabs="https://ptable.com/wiki/compounds/A/Sildenafil" title="Sildenafil">Sildenafil</a></li>
<li><a href="Tadalafil.htm" tppabs="https://ptable.com/wiki/compounds/A/Tadalafil" title="Tadalafil">Tadalafil</a></li>
<li><a href="Vardenafil.htm" tppabs="https://ptable.com/wiki/compounds/A/Vardenafil" title="Vardenafil">Vardenafil</a></li>
<li>VUF-6002</li>
<li>WY-46824</li>
<li>Zipeprol</li></ul>
</div></td></tr></tbody></table></div>










<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>